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Abstract 
Introduction/Aim:  
Angiogenesis is an integral part of tumour growth and development. Endothelial cell 
proliferation, migration and differentiation are the main hallmarks of this physiological 
process. From this, the use of antiangiogenic therapy have brought about a range of 
licensed FDA approved agents (that are also used by the NHS), that aim to regress tumour 
induced angiogenesis. However, issues such as: drug resistance, evasion and poor 
efficacy have limited the use of antiangiogenic therapy as a main stake in anti-cancer 
therapy. The need for multi-targeted or combinatorial therapies are ever more needed to 
enhance the current use of these drugs.  
Therefore, in an attempt to identify novel compounds that exhibit antiangiogenic activity, 
a group of 1-3-diphenylpropenones (chalcones) were designed, synthesised and 
biologically evaluated using AH1 (2-chloro-2’5’-dihydroxychalcone) as the parent 
compound.   
Methods: 
Chalcones were synthesised using variations of the Clasien-Schmidt condensation 
reaction, to develop a compound library based on AH1 (the parent compound). 
Thereafter, using HUVECs as an angiogenesis model, the effects of the compounds on 
HUVEC proliferation and migration were evaluated. This was carried out using the MTT 
cell proliferation assay and the wound healing “scratch” assay. Therein mechanistic 
evaluation was carried via gel electrophoresis and chemiluminescence western blot.  
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Main findings:  
Structure activity relationships (SARs) studies identified, that novel compounds AH9 (2-
bromo-2’5’-dihydroxychalcone) and AH12 (2-nitro-2’5’-dihydroxychalcone) were 
shown to exhibit strong anti-proliferative activity along with AH1. Other synthesised 
derivatives containing different functional groups such as, alkoxy, halogen and methyl 
did not exhibit similar activities to AH1. The culmination of structure activity relationship 
suggested that 2’5’-dihydroxy moiety was important to the observed activity only in 
conjunction with 2-chloro or now 2-bromo substitution on the other phenyl ring. Due to 
AH9’s better drug likeness over AH12, AH9 and AH1 were taken forward as the lead 
candidates. 
Anti-migratory analysis of lead candidates and licensed drug Sorafenib were conducted 
against HUVECs. AH9 (p < 0.0007) was shown to exhibit significantly more potent 
inhibitory effects on endothelial migration than AH1 (p = 0.19) and Sorafenib (p = 0.41) 
over the 8 hour time course study when compared to the untreated control. Mechanistic 
evaluation identified that AH9 could be exerting its anti-proliferative and potent anti-
migratory activity via inhibiting ERK kinase phosphorylation, this was seen at 10µM (p 
< 0.0001).  
Discussion and conclusion: 
To summarise, anti-proliferative and potent anti-migratory activity, towards HUVECs, of 
a novel molecule AH9 have been identified showing significant effects against two 
hallmarks of the angiogenesis cascade. AH9 presents a strong case as an agent capable of 
being developed as an angiogenesis inhibitor for anti-angiogenic therapy.  
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1.1 Cancer 
 
Cancer was the second leading cause of death worldwide (8.8 million) in 2015 (WHO, 
2018). Based on the current trends of the major cancers worldwide, prevalence of new 
cases will increase to 23.6 million by 2030, an increase of 68% compared to 2012 (Bray 
et al., 2012; Ferlay et al., 2015).  According to a study by Laudicella and colleagues in 
2010, cost of the four main cancers on the NHS was £1.5 billion (Laudicella et al., 2016).  
Cancer or tumours are defined as “abnormal cells dividing in an uncontrollable fashion” 
(Yu and Jove, 2004). Tumours are the result of uncontrolled cell proliferation. They can 
arise as a result of tumour suppressor genes being inactivated or tumour growth genes 
being overexpressed. These mutations can be the result of inherited or environmental 
conditions. Only 5-10% of cancer are the result of an inherited genetic defect (Anand et 
al., 2008; Roukos, 2009). The remaining 90-95% can be the consequence of several 
environmental triggers such as: smoking, diet, lifestyle, stress, infections, radiations and 
pollutants (Anand et al., 2008). The Knudson two hit hypothesis (Knudson, 2001) is a 
model that proposes that two “hits” are required for tumour development. The “first hit” 
is a genetic predisposition to develop a particular type of cancer, but, to trigger 
tumourigenesis, the “second hit” is needed and can arise from an environmental factor 
whether acute or chronic (Knudson, 2001).  
Significant amounts of research have gone into better understanding tumour development 
from a molecular biological standpoint (Vander Heiden and DeBerardinis, 2017). Many 
views have been put forward on the key components needed for tumour development 
such as: causes, molecular environments, key signalling molecules, mutations and many 
more (Cooper, 2000; Hanahan and Weinberg, 2011). It is because of this type of research 
that more targeted anti-cancer therapies have been developed (Weinstein and Joe, 2006).   
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1.1.1 Hallmarks of Cancer 
 
The hallmarks of cancer are a list of fundamental steps in cancer development. They 
provide therapeutic targets for anti-cancer drugs, as illustrated in Figure 1.  
 
 
 
 
 
 
 
 
 
Figure 1 Current targets in anticancer therapy. 
The 10 hallmarks illustrated above provide a key set of targets on which anti-cancer agents have 
been modelled from. These hallmarks enable the use of different form of anti-cancer studies i.e. 
anti-mitotic to anti-angiogenic agents. Adapted from (Hanahan and Weinberg, 2011). 
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1.1.1.1 Sustaining Proliferative Signalling  
 
Sustained chronic proliferation is an integral part of tumour survival (Feitelson et al., 
2015). The body maintains homeostasis of growth signals to ensure normal regulated 
tissue growth. When this is deregulated in tumours, uncontrolled proliferation can occur. 
Tumour cells can also release elevated levels of growth factors, causing autocrine 
proliferative stimulation (Heldin, 2012).  
1.1.1.2 Evading Cell Growth Suppressors  
 
Under normal conditions, tumour suppressor genes control cell growth (Vogelstein and 
Kinzler, 2004). Two suppressor genes, that encode RB (retinoblastoma-associated) and 
TP53 (tumour protein 53) proteins control cell growth functions, whether it is 
proliferation, activating senescence or triggering apoptosis (Hanahan and Weinberg, 
2011). Both proteins operate in different ways to maintain normal cell division; RB 
protein transduces extracellular signals that inhibit growth, whereas TP53 protein 
responds to intracellular signals stemming from cell stress or abnormalities (Sherr and 
McCormick, 2002).  
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1.1.1.3 Resisting Cell death  
 
Programmed cell death by apoptosis is a well-established natural defence against tumour 
development (Evan and Littlewood, 1998; Lowe, Cepero and Evan, 2004; Adams and 
Cory, 2007). The mechanism of apoptosis is governed by upstream regulators and 
downstream effectors (Adams and Cory, 2007). These regulators can be further 
categorised into receiving and transmitting extracellular and intracellular signals. 
Together or independently these pathways activate proteases, usually capases that cause 
a cell wide cascade of proteolysis and ultimately cell death. Adams and Cory (2007) also 
stated that the “apoptotic trigger” that relays the signals between the regulators and 
effectors is controlled by neutralising pro and antiapoptotic proteins belonging to the Bcl-
2 family (Lindsten et al., 2000). Bcl-2 and similar proteins like Bcl-x and Bcl-w are 
inhibitors of apoptosis, they work mostly by suppressing Bax and Bak proapoptotic 
proteins (Adams and Cory, 2007).  
Tumour cells can evolve to evade these regulatory mechanisms, i.e. avoiding 
programmed cell death, most commonly through the loss of TP53 tumour suppressor 
function (Hanahan 2011). Other possible routes of evasion include increasing the 
expression of antiapoptotic regulators like Bcl-2 and surviving signals (Igf1/2), or 
decreasing proapoptotic controllers such as Bax, Bim, Puma (Hanahan and Weinberg, 
2011). Autophagy is another physiological process that can both facilitate and suppress 
tumour growth (White, 2012). It is a physiological “housekeeping” mechanism that 
maintains organelle function and minimises build-up of toxic cellular waste.  Autophagy 
can support tumour growth through intracellular recycling of the cellular waste, 
suppression of p53 protein and upregulation of mitochondrial function (White, 2015).  
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1.1.1.4 Enabling Replicative Immortality  
 
It is a widely accepted notion that normal functioning cells have a limited number of 
continuous cell cycles (Shay and Bacchetti, 1997; Naasani, Seimiya and Tsuruo, 1998; 
Rudolph et al., 1999; Harley, 2008; Hainaut and Plymoth, 2013; Yaswen et al., 2015). 
There are two physiological processes that ultimately prevent unlimited replication. 
These are cell senescence, a permanent state of non-proliferative viability and crisis which 
ultimately involves cell death. The general process dictates that as numerous cell cycles 
occur, a point comes where senescence is triggered and thereafter any cells that remain 
proliferative enter the crisis phase where most cells die. Similar to the growth of 
antibiotic-resistant bacteria, a small population of cells survive this two part process. 
Therefore by evading cell senescence and crisis tumour cells can become immortalised 
(Hanahan and Weinberg, 2000, 2011).  
Several reports (Counter ’ et al., 1992; Hemann et al., 2001; Bailey and Murnane, 2006) 
support the concept that telomeres, which progressively become shorter over cycles, lose 
their ability to stabilise chromosomal DNA. Telomeres, are protective caps at the end of 
DNA strands. Hanahan and Weinberg (2011) argued the degree and rate of “telomere 
shortening” could be viewed as a biological clock device to assess the lifespan of cells 
(Hanahan and Weinberg, 2011). Telomerase, a specific DNA polymerase, can catalyse 
the process of adding telomeric segments to the ends of telomeric DNA. This is a crucial 
process to maintain cell viability over continuous cell cycles (Harley, 2008). A 
mechanism for maintaining telemetric DNA at high enough levels to avoid triggering cell 
senescence or crisis is via upregulating the amount of telomerase available (Hanahan and 
Weinberg, 2011). Therefore inhibiting telomerase activity could be seen as a potential 
anti-cancer avenue (Harley, 2008) 
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1.1.1.5 Activating Invasion and Metastasis  
 
In tumours, invasion and metastases can be viewed as a multistep process referred to as 
the invasion- metastasis cascade (Talmadge and Fidler, 2010). As tumour cell develop, 
cell to cell adhesion molecules can be disrupted allowing clusters of tumour cells to 
dissociate from the primary tumour into nearby capillaries or lymphatic vessels. This can 
increase the likelihood of metastasis (Martin et al., 2013). E-cadherin, a key adhesion 
molecule, has been shown to be an antagonist to invasion and metastasis, leading to 
reports of it being downregulated in human carcinomas (Cavallaro and Christofori, 2004; 
Berx and van Roy, 2009).  
1.1.1.6 Inducing Angiogenesis  
 
Angiogenesis is the formation of new blood vessels from pre-existing vasculature, it is 
vital in normal physiological processes such as healing of wounds, reproduction, growth 
and development (Folkman, 1995). It has been recognised that angiogenesis is a major 
factor in many severe and debilitating diseases from stroke and cardiovascular disease, to 
age related macular degeneration (AMD) and cancer (Carmeliet and Jain, 2000). 
Angiogenesis is regulated by precise balance between angiogenic stimulatory and 
inhibitory factors (Li et al., 2012). Disruption of this balance can contribute to tumour 
development through proliferation of tumour vasculature (Vasudev and Reynolds, 2014). 
This section will be further expanded on later (see Section 1.2 onwards).   
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1.1.1.7 Emerging hallmarks and characteristics 
 
There are several core developments in cancer biology that have gained attention as 
targets for anti-cancer therapy. In turn these developments lead to qualities the tumour 
can then possess. Hanahan and Weinberg (2011) highlighted the following developments 
(Hanahan and Weinberg, 2011).   
Spontaneous mutations  
Due to the maintenance system that governs repairing faulty DNA in cells, spontaneous 
mutations occur rarely. But when they do occur, these mutations do not just affect cell 
proliferation directly but also energy metabolism. The factors that affect fuelling cells can 
be reprogrammed via these function-altering mutations to essentially accelerate tumour 
cell division (Korkola and Gray, 2010).  
Immunoediting 
Immunoediting is one the key ways in which tumours evade the immune system (Vinay 
et al., 2015)  Other forms of evasion include,  tumours presenting weak antigens on the 
cell surface to avoid immune recognition, or increasing the expression of 
immunoregulatory molecules to develop an immunosuppressive tumour environment 
(Muenst et al., 2016). 
Tumour promoting inflammation 
It has been readily known that much of the inflammation occurring in a tumour 
environment contributes to tumour progression, from a preliminary neoplastic tissue to a 
fully formed malignant tumour (Visser, Eichten and Coussens, 2006; Qian and Pollard, 
2010). This ability of immune cells, in particular innate immune cells to enhance tumour 
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progression can contribute to tumours evading immune destruction. Chronic 
inflammation contributes to tumour progression by causing DNA damage. NF-kB has 
been known to be a key tumour promoter in chronic inflammatory environment by 
inhibiting apoptosis of cells destined to be tumourigenic (Karin and Greten, 2005). 
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1.2 The Angiogenesis process 
 
There are two known types of angiogenesis, sprouting and intussusceptive (Adair and 
Montani, 2010). Although both occur in nearly all tissues types, sprouting angiogenesis 
is more readily occurring (Hillen and Griffioen, 2007). Intussusceptive angiogenesis, also 
known as splitting angiogenesis tends to occur quite rapidly. It differs to sprouting 
angiogenesis as it is more about reorganisation of existing vasculature (splitting blood 
vessels into two) as opposed to endothelial cell migration and proliferation (Kurz, Burri 
and Djonov, 2003). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2 Forms of angiogenesis.  
A representation showing the difference between sprouting and intussusceptive 
angiogenesis. Sprouting angiogenesis shows the new sprouting vessel maturing and 
developing form the original vessel similar to a branch extending from a tree. 
Intussusceptive angiogenesis looks at forming two blood vessels by splitting one vessel 
into two. Figure adapted from (Prior, Yang and Terjung, 2004) 
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Upon stimulation by a pro-angiogenic signalling mediator (e.g. VEGF), endothelial cell: 
sprouting, proliferation, migration and differentiation can occur as described below 
(Klagsbrun and Moses, 1999; Tan et al., 2003; Adams and Alitalo, 2007).  
1) Tip cell selection from successful sprouting cells 
Sprouting cells exposed to the highest concentrations of VEGF become the tip cell to lead 
the angiogenesis process.  
2) Activated endothelial cells secret matrix metalloproteinase (MMPs) 
Basement membrane degradation occurs via MMPs and other extracellular proteinases to 
provide space for the angiogenic vessel to migrate.  
3) Endothelial cell migration towards the angiogenic stimulus 
A tip cell guides the developing capillary sprout through the extracellular matrix towards 
the angiogenic stimulus e.g. VEGF.  
4) Endothelial cell proliferation and sprouting into the stromal space 
Stalk cell proliferate and elongate to extend the developing vessel towards the angiogenic 
stimulus.   
5) Formation of tight junctions and the establishment of a new basement membrane 
Cell to cell adhesion molecules are recruited to form blood vessel loops that transform 
the premature vessel into a fully formed blood vessel. 
6) Endothelial cell organisation and oxygenation  
Tips cell fuse together forming a continuous lumen to allow oxygenation. Once cells are 
oxygenated VEGF levels return to a quiescent state.  
7) Pericytes recruitment to stabilise newly formed blood vessel. 
Pericytes are gathered to stabilise and mature the vessel. New basement membrane is 
desposited and blood flow is initiated (Hanahan and Folkman, 1996).  
 
Figure 3 highlights the many molecules involved in the highly regulated angiogenic 
process. 
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Stimulators 
VEGF 
PIGF 
FGF 
PDGF 
EGF 
MMP-2, MMP-9 
COX-2,  mTOR 
ROS 
Others 
Inhibitors 
TSP-1 
PF-4 
Angiostatin 
Endostatin 
Tumstatin 
Interferon α, β, γ 
TIMPs 
AMPK 
Others 
Figure 3 Angiogenic stimulators and inhibitors. 
In a microscopic tumour there are many angiogenic 
stimulators and inhibitors (adapted from Albini et al. 2012) . 
34 
1.2.1 Targeting Angiogenesis  
 
Different forms of angiogenesis exist, physiological angiogenesis, lymphangiogenesis 
and pathological angiogenesis (Jussila and Alitalo, 2002). Folkman (2007) described how 
pathological angiogenesis can persist for years, leading to the rationale of “angiogenesis-
dependent diseases” (Folkman, 2007). This term explains how angiogenesis can 
contribute to disease progression in several diseases, including AMD, cancer, rheumatoid 
arthritis and atherosclerosis. As a result, angiogenesis has become a target for clinical 
intervention (Folkman, 1995). It was proposed by Folkman (2007) that due to 
angiogenesis being an integral part of a range of diseases, it could be deemed as an 
organising principle for disease treatment as a whole (Folkman, 2007).  
For tumours, angiogenesis has a fundamental role in its growth and development, which 
is why this process has been targeted for anti-cancer research.  Over the years many have 
hypothesised ways to disrupt angiogenesis in hope to starve the tumour of its blood supply 
and bring neoplastic cell proliferation to a halt (Ferrara and Kerbel, 2005; Folkman, 2006; 
Mahar et al., 2009; Gotink and Verheul, 2010; Ebos and Kerbel, 2011; Vasudev and 
Reynolds, 2014). Weidner et al. (1991), found that the greater the degree of angiogenesis 
detected in a primary tumour, the worse the prognosis, essentially establishing a direct 
correlation between angiognenesis and tumour prognosis. In tumours, the balance of 
angiogenic stimulators and inhibitors is altered. Thus, the “angiogenic switch” is turned 
on (Figure 4) and the level of stimulators considerably exceeds the level of inhibitors, this 
is commonly seen in a tumour environment.  
Bergers et al. (2003) highlighted that the angiogenic switch is largely seen as a rate 
limiting phase in the multi-stage process of carcinogenesis (Bergers and Hanahan, 
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2008a). VEGF overexpression is one of many ways that can shift the balance of 
angiogenic factors leading to tumour induced angiogenesis (Hanrahan et al., 2003). This 
consequently causes the development of a complex arrangement of capillaries in close 
proximity to tumour cells (Nagy et al., 2009). As a result, this allows sustainable 
transportation of oxygen and nutrients to increase cell growth as well as waste removal. 
Figure 5 highlights some of the mediators involved in tumour induced angiogenesis. 
 
  
 
 
 
 
 
 
 
 
Tumour induced angiogenesis can ultimately lead to an increase in the probability of 
tumour cells entering the bloodstream, contributed by an increased interstitial pressure 
causing “leaky vessels” (Jain, 2005). Factors such as, irregular shaped cells and weak cell 
to cell junctions also play a role in the cause of leaky vasculature. This in turn can lead to 
possible wide spread metastasis and poor prognosis (Ferrara and Kerbel, 2005). 
Stimulators Inhibitors 
Angiogenesis switch 
OFF 
ON 
Figure 4 the angiogenic switch.  
The angiogenic switch refers to when the amount of angiogenesis activators outweigh the effects 
of angiogenic inhibitors (Bergers and Benjamin, 2003).  
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Consequently, this links back to the direct correlation first discovered by Weidner et al. 
(1991) between increased angiogenesis and poor prognosis. Due to metastasis, as a result 
of unsuccessful clinical intervention (Plank and Sleeman, 2003), other studies have also 
suggested a link between angiogenesis and tumour lethality (Kim et al., 1993; Bikfalvi, 
1995; Bielenberg and Zetter, 2015).  
 
Figure 5 Sprouting angiogenesis. 
In sprouting angiogenesis there are several key mediators (VEGF, PDGF, bFGF) that are released from a 
tumour, activating the angiogenesis process via receptor binding on an endothelial cell surface. 
Extracellular matrix proteinases are released by activated endothelial cells to breakdown the existing 
extracellular matrix to provide space for the sprouting blood vessel (Folkman, 2007). 
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1.2.3 VEGF and VEGFRs 
 
Amongst the many angiogenic factors seen in Figure 3, the most potent proangiogenic 
factor is vascular endothelial growth factor (VEGF) (Olsson et al., 2006). The VEGF 
family comprises of several glycoproteins known as VEGF-A, VEGF-B, VEGF-C, 
VEGF-D and VEGF-E. VEGF-A is more commonly referred to as VEGF, and is the 
centre of attention in terms of its direct importance and efficacy in stimulating VEGFR 
signalling pathways (Hicklin and Ellis, 2005, Rapisarda and Melillo, 2012). VEGF 
ligands exert their angiogenic effects by binding to VEGF receptors (VEGFRs), with 
three VEGFRs known to date, VEGFR-1, VEGFR-2 and VEGFR-3. These are 
predominantly found on endothelial cell surfaces (Neufeld et al., 1999). VEGFRs are 
receptor tyrosine kinase (RTK) and are activated upon ligand-mediated dimerisation. The 
difference RTKs have to G protein couple receptors (GPCR) are that multiple cellular 
responses can occur from one dimerisation event of a RTK dimer, whereas only one 
cellular response can occur from a GPCR dimer. This is due to the multiple tyrosine 
molecules on the intracellular domain of a RTK (Shibuya, 2011). VEGF signalling 
induces migration, differentiation and increased vascular permeability of endothelial 
cells; these are all vital processes in angiogenesis. Figure 6 illustrates the VEGF-VEGFR-
2 pathway highlighting specifically the MAPK/ERK pathway. ERK 1/2 kinases are key 
mediators in the signalling cascade to trigger endothelial cell proliferation and migration. 
The MAPK/ERK pathway contributes to a whole host of cellular processes such as: 
regulating T cell activation, phosphorylation of the p53 transcription factor, activation of 
phospholipase A2 (PLA2) in mast cells and more (Shaul and Seger, 2007). Regulation of 
this pathway is key to prevent tumourigenesis, as overexpression of ERK 1/2 can lead to 
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inhibition of apoptosis. In turn this can lead to over proliferation of cells and as a result 
tumour development.  
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Figure 6 A diagrammatic summary of the RAS RAF ERK pathway.   
The diagram illustrated the MAPK phosphorylation cascade as a result of VEGFR-2 activation by VEGF.  Kinase suppressor of RAF (KSR) is used as a scaffold protein to help 
facilitate the phosphorylation cascade. Once complete, ERK activates the transcription factors Cos and Jun-1 which target the AP-1 promoter gene region, this in turns helps to 
facilitate proteomic changes to increase proliferation, migration and survival. Bevacizumab and Sorafenib represent two current antiangiogenic therapies, target the growth 
factor VEGF or key receptors and mediators. Raf-1 holds great importance in this pathway as it can be stimulated by both VEGFR-2 and FGFR, hence it has been a target for drug 
intervention (Sorafenib). (Maitland et al., 2010) 
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VEGFR-1, is commonly expressed on endothelial cells and macrophages in adulthood 
(Shibuya, 2006). Amongst the three VEGFRs, VEGFR-1 is unique as it expresses two 
types of mRNA, a RTK and a soluble free circulating truncated protein referred to as 
sVEGFR-1 (s-Flk-1) (Laird et al., 2002; Shibuya, 2006). Both VEGFR-1 and s-Flk-1 
have been viewed as decoy receptors to VEGFR-2 essentially trapping VEGF, this notion 
has been exploited as an antiangiogenic approach by increasing the amount of free 
circulating VEGFR via the use of aptamers (this is further described in section 1.3). 
Although VEGFR-1 is largely a receptor for VEGF, it has the ability to allow the binding 
of VEGF-B and placental growth factor (PIGF), another proangiogenic factor (Malik et 
al., 2006). This ability has been heavily targeted for anti-VEGF therapy, as inhibiting this 
receptor could lead to several pro-angiogenic signalling pathways being halted. Figure 7 
illustrates the different VEGF to VEGFR binding interactions.  
 
Figure 7 VEGF isoforms and VEGFR receptors.  
Schematic diagram of VEGFA VEGFB VEGFC VEGFD isoforms and PLGF binding to VEGF receptors. The 
diagram displays how VEGF B binds to VEGFR-1 but how the most abundant isoform VEGFA can bind to 
both VEGFR-1 and VEGFR-2. It also illustrates how VEGFC and VEGFD are mostly associated with VEGFR-3 
found on lymphatic vessels.  Diagram adapted from (Olsson et al., 2006).  
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In relation to VEGF, VEGFR-2 is the main pro-angiogenic receptor in angiogenesis. 
VEGFR-2 mediates the downstream effects of VEGF in angiogenesis specifically its role 
in micro vascular permeability, endothelial cell proliferation, invasion, migration and cell 
survival. Activation of VEGFR-2 has shown potent endothelial cell activity both in in 
vitro and in vivo models, heavily supporting the concept of angiogenesis activation via 
VEGFR-2 alone (Yancopoulos et al., 2000; Hicklin and Ellis, 2005).  
VEGFR-3 is most commonly found in lymphatic endothelial cells (Witmer et al., 2001).  
Lymphangiogenesis refers to the formation of new lymphatic vessels and is essential in 
physiological processes such as homeostasis, metabolism and immunity (Maby-El 
Hajjami and Petrova, 2008; Stacker and Achen, 2009). It is most active during embryonic 
development and less so postnatal. As a result it is seen in adults under pathological 
conditions such as inflammation and tumour growth (Christiansen and Detmar, 2011). 
Therefore antiangiogenic approaches could help combat neoplastic cells metastasising via 
the lymphatic system to lymph nodes. 
VEGF plays a vital role in the progressive stages of tumour growth along with the 
increasing induction of many other angiogenic factors. The change from high VEGF 
dependency in early stages, to an array of proangiogenic factors in advanced stages, could 
be further investigated for antiangiogenic therapy (See Figure 8).  
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VEGF induces the secretion of multiple enzymes and proteins vital for degradation of the 
extracellular matrix, e.g. matrix metalloproteinases, metalloproteinase interstitial 
collagenase and serine proteases such as tissue-type plasminogen activator. The 
extracellular matrix is the non-cellular part found in all tissue types. It provides the 
essential scaffolding to support the cellular components of tissues and initiates key 
biological cascades important in tissue morphogenesis and differentiation (Frantz et al., 
2010).  The activation of these compounds causes the endothelial cells to form sprouts 
from the existing blood vessel, starting the angiogenic process. What is key is that the 
absence, or inhibition, of VEGF can cause the extracellular matrix to undergo apoptosis 
and trigger vessel regression, i.e. cause an antiangiogenic episode (Plank and Sleeman, 
2003).  
Figure 8 VEGF dependency in stages of tumour growth. 
As the tumour becomes more vascularised the dependency on VEGF signalling is reduced and other non-VEGF 
angiogenic stimulators are utilised to further the development of the tumour, adapted from (DeVita, Hellman and 
Rosenberg, 2005). 
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Angiogenesis is essential to provide a supply of blood and oxygen to nearby tissues; in 
tumours this enables growth. However pathological angiogenesis produces more 
dysfunctional vessels as seen in Figure 9. Specifically, it is the overexpression of VEGF 
that can result in a hyperperfused, hyperpermeable neovasculature, which is often 
complex, leaky and irregular compared to normal vasculature. 
Although the original concept behind antiangiogenic therapy was to starve tumours of 
oxygen, studies have revealed a concept termed tumour vascular normalisation (Jain, 
2005). It was initially seen as an unexpected property of antiangiogenic therapy, but 
further studies were able to clarify how bringing the tumour vascular to a more controlled 
state i.e. by inhibiting the overexpression of VEGF, was linked to the normalisation 
observed (Huang et al., 2013; Shi, Chen and Huang, 2013). Therefore, it has now become 
a key concept behind antiangiogenic therapy because the normalised vasculature allows 
for an increase in chemotherapeutic drug delivery and consequently drug efficacy 
(Carmeliet and Jain, 2011). 
Figure 9 Normal and tumour vasculature. 
The difference in vasculature between normal and tumour environments is that tumour vasculature is often irregular and 
hyperpermeable whereas the normal physiological vasculature is more uniform and tightly regulated (Weinberg, 2013) 
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Longo et al. (2002) recognised that expression of VEGF in normal adult vasculature was 
independent of survival, stability and normal function (Longo et al., 2002). Whereas in 
tumour vessels, VEGF was seen as a key survival factor (Longo et al., 2002). It is 
arguably the most potent proangiogenic factor as many studies such as one by Ferrara and 
Kerbel (2005) observed that the majority of tumours analysed in his study showed 
elevated levels of VEGF (Ferrara and Kerbel, 2005; Jain et al., 2005; Olsson et al., 2006a; 
Shibuya, 2011; Rapisarda and Melillo, 2012).  
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1.2.4 Non-VEGF Modulators of Angiogenesis 
 
Non-VEGF pathways appeared to gain importance when VEGF is inhibited. Growth 
factors like the fibroblast growth factor (FGF) family are deemed as key mediators of 
angiogenesis (Lieu et al., 2011). They have shown similar and, in rare cases, superior 
effects to VEGF (Pepper et al., 1992; Turner and Grose, 2010). In an attempt to better 
understand the importance of FGF in tumour angiogenesis, Compagni and colleagues 
(2000) used adenoviral sflk-1 (AdsFlt) and sFGF (adsFGFR) receptors to interfere with 
VEGFR-1 and FGFR (Compagni et al., 2000). They found that adsFlt predominantly 
impaired initiation of tumour angiogenesis, whereby adsFGFR disrupted the maintenance 
of tumour angiogenesis (Compagni et al., 2000). 
Angiopoietins are a family of vascular growth factors that are part of the ANGPT-TIE2 
pathway (Little, 2015). This pathway is crucial in the angiogenesis process (Saharinen, 
Eklund and Alitalo, 2017). Studies have shown that the pathway is critical in triggering 
and supporting tumour induced angiogenesis (Ferrara and Kerbel, 2005; Pouysségur, 
Dayan and Mazure, 2006; Huang et al., 2010). Angiopoietin 1 (ANGPT1) is considered 
to be responsible for blood vessel maturation and stability (Saharinen, Eklund and Alitalo, 
2017). Angiopoietin 2 (ANGPT2) binds to the TIE-2 receptor and acts as an antagonist 
to ANGPT1 (Little, 2016). It is also upregulated in hypoxic and inflamed environments 
(Blumenkranz et al., 2013). In a tumour setting, evidence has shown that increased 
ANGPT2 expression in tumours results in poor prognosis for patients (Loges et al., 2005; 
Hou et al., 2008; Koenecke et al., 2010). ANGPT2 has been identified in melanomas, 
glioblastomas, breast cancer, colorectal cancer and renal cell carcinoma (Sfiligoi et al., 
2003; Helfrich et al., 2009; Goede et al., 2010; Wang et al., 2014; Scholz et al., 2016). 
Whereas increased ANGPT1 levels, responsible for increasing vessel stability, has shown 
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to normalise tumour vasculature enabling better drug delivery (Winkler et al., 2004; 
Falcón et al., 2009; Coxon et al., 2010).  
Matrix metalloproteinases (MMP) are a group of proteinases that play an important role 
in tumour growth (Egeblad and Werb, 2002). Their function of extracellular matrix 
degradation via collagen breakdown are critical in the angiogenesis process (Foda and 
Zucker, 2001). Studies have revealed particular MMPs and their involvement in tumour 
induced angiogenesis (Bergers et al., 2000). Iurlaro et al. (1999) identified that increased 
levels of MMP-2 and MMP-9 resulted in enhanced angiogenesis and tumour invasiveness 
(Iurlaro et al., 1999). In a murine study, cancer colonies in lungs were reduced by the 
downregulation of MMP-9 (Itoh et al., 1998, 1999). MMP-7, 9 and 12 overexpression 
has also been identified in squamous cell carcinoma (Impola et al., 2004). 
Cyclooxgenase (COX) enzymes, in particular COX-2, have a well understood role in 
inflammation (Ricciotti and FitzGerald, 2011). They are responsible for catalysing the 
formation of prostanoids (Smyth et al., 2009). But they also play an important role in 
activating angiogenesis, as they are expressed on many tumour cells as well as endothelial 
cells (Gately and Li, 2004). The proangiogenic effects are as a result of arachidonic acid 
metabolism forming metabolites specifically epoxyeicosatrienoic acids (EETs) that are 
angiogenic (Masferrer et al., 2000; Rand et al., 2017). Furthermore, COX-2 is expressed 
by tumour endothelium in various tumours types such as human colon and prostate cancer 
whereas in normal quiescent endothelial cells only COX-1 is found (Leahy et al., 2002).  
It is evident that non-VEGF growth factors play a pivotal role not only in angiogenesis 
itself but also in anti-VEGF drug resistance. Preclinical models have revealed how non-
VEGF growth factors support the development of tumour induced angiogenesis (Plate et 
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al., 1992; Kim et al., 1993). One study revealed FGF-2 levels increase with VEGF-axis 
inhibition (Casanovas et al., 2005). While blockade of FGF2 in anti-VEGF resistant 
tumour models in vivo caused reduction in tumour growth (Allen, Walters and Hanahan, 
2011). Another study identified upregulation of FGF-2 in RIP-TAG tumours after 
treatment with a VEGFR-2 inhibitor (Casanovas et al., 2005) Several other studies have 
reported high levels of PDGF-BB expression in highly vascularised malignant 
glioblastoma; as well as elevated FGF-2 levels in advanced vascularised tumours (Cao 
and Pettersson, 1990; Soutter et al., 1993; Malek et al., 1997; Auguste, Javerzat and 
Bikfalvi, 2003; Heldin, 2004; Ostman and Heldin, 2007). Both of these non-VEGF 
angiogenic factors (FGF-2 and PDGF) have been linked to tumour progression and 
metastasis (Soutter et al., 1993; Nguyen et al., 1994).  
These findings support the notion that multi targeted receptor (RTKIs) inhibitors such as 
sunitinib, sorafenib and regorafenib (described in 1.3.1) are needed to minimise escape 
mechanisms, for instance, non-VEGF mediated angiogenesis.   
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1.3 Antiangiogenic Therapy 
 
Antiangiogenic therapies are based on preventing, disrupting or regressing neo vascular 
formation (Samant and Shevde, 2011; Al-Abd et al., 2017). Approaches to antiangiogenic 
therapy are conducted via three methods highlighted in Figure 10.   
 
The first approved treatment was Avastin (bevacizumab) in 2004, a monoclonal antibody 
that binds to VEGF preventing it binding to a VEGFR (Ferrara and Kerbel, 2005; Kamba 
and McDonald, 2007). Originally it was licensed to be used in conjunction with 
intravenous 5-fluorouracil based chemotherapy as a first or second treatment for 
colorectal carcinoma. Two years later it was approved in combination with anti-mitotic 
agent paclitaxel and anti-neoplastic agent carboplatin for first line treatment against 
various forms of non-small cell lung cancer (NSCLC), (Sandler et al., 2006). As of 2014, 
the FDA approved its use against metastatic cervical cancer with paclitaxel and cisplatin.   
Figure 10 General mechanism of FDA approved antiangiogenic therapies (Folkman, 2007).  
There are therapies that block angiogenic receptors (Sutent), neutralise VEGF ligands (Avastin) or inhibition the 
production of VEGF and other key angiogenic stimulators (Iressa).  
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Ranibizumab and aflibercept are two licensed drugs that work in similar ways to 
bevacizumab, i.e. agents that bind to VEGF. Ranibizumab is a monoclonal antibody 
fragment derived from the same mouse antibody as bevacizumab (CATT Research Group 
et al., 2011). Although it has similar modes of action to bevacizumab its price per single 
dose is considerably higher, as a single dose costs around £1450 whereas bevacizumab 
costs £35 (CATT Research Group et al., 2011). Aflibercept acts as decoy receptor to bind 
to circulating plasma VEGF as “VEGF trap”, it is composed of domains from VEGFR-1 
and VEGFR-2. It also has the ability to bind to PLGF and VEGF-B (Saharinen, Eklund 
and Alitalo, 2017).  
Aptamers such as pegaptanib also neutralise VEGF but via a different approach.  
Aptamers are DNA or RNA oligonucleotide strands that can specifically bind to selective 
VEGF-isoforms in particular VEGF-165; which is the most abundant splice variant of 
VEGF-A (Enseleit, Michels and Ruschitzka, 2010).  
Receptor tyrosine kinase inhibitors (RTKIs) are a group of drugs that target a broad range 
of pro-angiogenic tyrosine kinase receptors (VEGFR, FGFR, PDGFR) (Ferrara and 
Kerbel, 2005), these have largely been the common focus of antiangiogenic drug 
discovery for many years (Morin, 2000). As of July 2015, 28 small molecular RTKI’s 
have been FDA approved for use against several types of cancer (Wu, Nielsen and 
Clausen, 2016). Many analogues and derivatives have been developed that either are: 
tyrosine kinase inhibitors, serine/threonine kinase inhibitors, dual protein kinase 
inhibitors or lipid kinase inhibitors. However, the overwhelming majority are tyrosine 
kinase inhibitors (Wu, Nielsen and Clausen, 2016). The most widely used RTKI is sutent, 
also known as sunitinib, it predominantly targets VEGFRs and PDGFRs (Abrams, Lee, 
et al., 2003; Abrams, Murray, et al., 2003). 
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Currently, two dual specificity kinase inhibitors have been approved, sorafenib and 
regorafenib. Dual specificity kinase inhibitors bind to receptors found on seperate 
signalling pathways. Sorafenib has the ability to target the RAF/MEK/ERK pathway in 
tumour cells and VEGFR/PDGFR tyrosine kinase receptors in the surrounding 
vasculature (Adnane et al., 2006),  regorafenib targets the VEGFR-2 and Tie-2 receptors 
(Saharinen, Eklund and Alitalo, 2017).     
 
 
 
 
 
 
 
 
 
 
 
 
 
 
51 
1.3.2 Limitations with Current Licensed Antiangiogenic Agents 
 
Inducing an antiangiogenic response with antibodies or tyrosine kinase inhibitors is 
effective for treating malignancy (Abdollahi and Folkman, 2010). Initial findings from 
phase III clinical trials have revealed improved survival with the use of multi targeted 
RTKI monothereapy, such as sunitinib and sorafenib, in gastrointestinal and renal 
tumours (Jain et al., 2005).  However, there is room for improvement in terms of efficacy 
and long term use (Fan et al., 2006). Jain and colleagues in 2005 expressed that optimised 
treatments are needed to prevent tumour escape and extend patient survival past 5 months 
(Jain et al., 2005).   
The rationale as to antiangiogenic therapies only showing efficacy towards some tumour 
cell types and not others is unknown, but the difference in the biological composition 
between tumour types may contribute (Vasudev and Reynolds, 2014).  
However antiangiogenic therapies are accompanied by various side effects. The most 
common side effect seen in nearly all drugs that inhibit anti-VEGF activity is 
hypertension. In clinical studies the first VEGF inhibitor, bevacizumab, was shown to 
have an overall hypertensive incidence of 32%, however, only 1% of patients developed 
a life threatening hypertensive crisis (Hurwitz et al., 2004; Kabbinavar et al., 2005). 
Hypertension is direct cause of VEGF inhibition, by reducing vasodilation via inhibition 
of nitric oxide production (Kamba and McDonald, 2007; Robinson et al., 2010).  
Therefore it has been viewed as a potential biomarker to monitor the desired effects of 
anti-VEGF therapies (Mir et al., 2009; Robinson et al., 2010). Other reported adverse 
effects include gastrointestinal perforation, haemorrhage, thromboses and in rare 
occurrences congestive heart failure (Kamba and McDonald, 2007). In another study with 
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bevacizumab against unresectable hepatocellular carcinoma,  serious bleeding 
complications were apparent in 11% of patients (Siegel et al., 2008).  
Similarly to bevacizumab, small molecule RTKIs create adverse effects. Common 
adverse reactions range from hypertension and mild bleeding, to infrequent but life 
threatening haemorrhages and ischaemic conditions (Kamba and McDonald, 2007). One 
study by Lee et al (2009) identified significant cutaneous toxicities in patients receiving 
sunitinib or sorafenib, with hand and food skin reaction seen as the most common effect 
(Lee et al., 2009). This was observed in 48% of patients treated with sorafenib (52 out of 
109 patients) and 36% of those treated with sunitinib (39 out of 119 patients) (Lee et al., 
2009). Verheul and Pinedo (2007) formulated a concise table (table 1) of the potential 
mechanisms underlying antiangiogenic therapy induced side effects (Verheul and Pinedo, 
2007). It was evident that the toxicities were varied, affecting a whole host of 
physiological processes. However, the research concluded that short term toxicities are 
generally manageable in clinical trials (Verheul and Pinedo, 2007).  
Table 1 Possible molecular mechanisms for the adverse drug reactions of angiogenesis inhibition. (Adapted from 
(Verheul and Pinedo, 2007)). 
Adverse drug reactions Possible underlying mechanism 
Bleeding, impaired wound healing Platelet dysfunction; decreased expression of 
endothelial tissue factor 
Hypertension Decreased NO and/or PGI2 production; 
inappropriate density vessels; vascular 
stiffness; disturbed endothelin function 
Hypothyroidism Disturbed thyroid cell function; reduced 
vascularity of thyroid 
Proteinuria and oedema Podocyte dysfunction owing to VEGF 
blockade; hypertension 
Dizziness, nausea, vomiting and diarrhoea Mucosa disturbance 
Skin toxicity including rash and hand-foot 
syndrome 
Epidermal cell apoptosis 
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Reformation of dysfunctional tumour vasculature is often seen when anti-VEGF therapies 
are stopped, and the re-emergence of endothelial cells and microvasculature occurs 
(Vosseler et al., 2005). Thus, the long-term capabilities of anti-VEGF therapies are vital 
in sustaining the antiangiogenic activity, and possibly preventing the angiogenic switch. 
Long term use of anti-VEGF therapies in itself can be problematic due to acquired 
resistance, poor drug delivery or long-term side effects. Therefore, this drawback could 
pave the way for the need of other long term non-VEGF alternatives. Figure 11 illustrates 
the current mechanism of action to inhibit VEGF signalling. Optimal combinations such 
as multi-drug approaches specific for antiangiogenic therapy, are still overlooked, 
especially with drug resistance and escape mechanisms identified with anti-VEGF 
therapy (Fan et al., 2006; Folkman, 2007; Loges, Schmidt and Carmeliet, 2010; Vasudev 
and Reynolds, 2014). Further investigations will help to identify the positive or negative 
consequences of antiangiogenic therapy in relation to the tumour, its growth and 
metastatic potential (Ebos and Kerbel, 2011). 
 
 
 
 
Figure 11 mechanisms to inhibit VEGF signalling:  
There are different mechanisms of which to inhibit VEGF signalling: a) binding to the VEGF b) 
binding to VEGFR-1 c) binding to VEGFR-2 d) introducing free soluble VEGF receptors e) 
utilising small-molecular intracellular and extracellular or intracellular RTKIs (Ferrara and 
Kerbel, 2005). 
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1.3.3 Antiangiogenic Drug Resistance 
 
Although anti-VEGF monotherapy has been shown to increase survival in patients with 
specific cancers, Jain and colleagues (2005) identified there has been noticeable tumour 
resistance and evasion against anti-VEGF therapies (Jain et al., 2005). In 2006, the 
founder of antiangiogenic studies, Judah Folkman, postulated the stubborn nature of 
tumours in response to mono-antiangiogenic therapy targeting a single protein, e.g. VEGF 
(Folkman, 2006, 2007). This anti-VEGF resistance has resulted in non-VEGF 
reactivation of angiogenesis via the FGF family (Casanovas et al., 2005). To add, anti-
VEGF therapies can cause increased amounts of plasma VEGF leading to increased 
VEGFR activation once the inhibitor is removed (Drevs et al., 2005; Motzer et al., 2006; 
Verheul and Pinedo, 2007).  
Figure 12 Two modes of resistance seen after exposure to antiangiogneic therapy demonstrating adaptive and non-
responsive evasions by tumours adapted (Bergers and Hanahan, 2008).  
Adaptive resistance represents a tumours ability to adapt after initial exposure to angiogenic inhibitors. Non-responsive 
resistances refer to a pre-existing attribute a tumour has, causing antiangiogenic therapy to be redundant in its effects.  
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According to Bergers and Hanahan (2008), emerging data suggests that antiangiogenic 
drug resistance falls into two categories, evasive and intrinsic as illustrated in Figure 12 
(Bergers and Hanahan, 2008). Evasive resistance refers to a tumour’s ability to adapt after 
an initial exposure to angiogenesis inhibitors in an attempt to evade the therapy and 
continue tumour growth (Loges, Schmidt and Carmeliet, 2010). Whereas intrinsic, also 
known as non-responsive, resistance describes a latent pre-existing condition within the 
tumour, rendering the antiangiogenic therapy ineffective (Bergers and Hanahan, 2008).  
Table 2 highlights the potential solutions that need to be developed to overcome tumours 
escaping or evading antiangiogenic therapy (Jain et al., 2005; Loges, Schmidt and 
Carmeliet, 2010). Using novel chemical scaffolds that target alternative pathways is a 
potential solution going forward. Chemical scaffolds such as chalcones have shown to 
exhibit antiangiogenic activity via downregulation of VEGFR-2 and signalling mediators 
e.g. ERK 1/2 and Akt (Mojzis et al., 2008; Lee et al., 2012; Mahapatra, Bharti and Asati, 
2015). This will be further expanded on in chapter 1.5.  Development of inhibitors 
targeting alternative proangiogenic factors could supplement current antiangiogenic 
therapies as a combinatorial or synergestic approach (Loges, Schmidt and Carmeliet, 
2010; Ebos and Kerbel, 2011).  
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Table 2 Possible solutions to counteract antiangiogenic drug resistance and evasion. 
Target alternative pathways, using combinatorial approaches or modifying drug dosage (adapted from 
Jain et al., 2005). 
    
Possible mechanisms 
Tumour does not 
respond to VEGF-
blockade 
Ineffective or no 
cytotoxic therapy 
Inefficient vasculature 
 
Acquired resistance to 
the antiangiogenic or 
cytotoxic agents 
Potential solution 
Use antiangiogenic 
agents that target 
alternative 
pathways 
Combine the 
antiangiogenic 
agent with 
effective 
cytotoxic 
Modify the 
dose/schedule of the 
antiangiogenic agent 
 
Use alternative 
antiangiogenic or 
cytotoxic agents 
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1.4 Preclinical design and development of small molecular anticancer drugs 
1.4.1 The drug discovery process 
 
The discovery of general anti-cancer drugs is a long-term process comprising of 
preclinical and clinical development. From target identification to a marketable drug, the 
process encompasses core fields of medicinal chemistry and pharmacology. 
Pharmacodynamics is often carried out in the early parts of drug discovery to identify a 
compound exhibiting a targeted activity. It is defined as the branch of pharmacology that 
focuses on the effects drugs on an organism and their mechanism of action. Whereas 
pharmacokinetics (focused on the effects of drug movement in an organism) is recognised 
in the latter stages to improve the qualities of drug likeness and effectiveness. All fields 
and parts of the process are interchangeable to form more of a drug discovery cycle as 
opposed to a rigid one way process. Figure 13 demonstrates the different stages that 
encompass the general drug discovery cycle.  
 
 
 
 
 
 
 
 
 
Figure 13 A diagrammatic representation of how a drug discovery cycle 
encompasses 4 key areas. 
Target selection, Hit discovery, candidate identification and clinical trials. The red box 
highlights the areas involved in this study (Hoelder, Clarke and Workman, 2012).  
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The hallmarks of cancer provide a useful guide for the development of a drug target. Once 
a target is selected, the “hit generation” phase occurs where “hit” compounds with 
preliminary biological activity must be generated. There are several routes for hit 
generation which are used independently or in combination. These approaches consist of: 
high-throughput screening, fragment screening, virtual screening, molecular docking 
design, nuclear magnetic resonance (NMR) screening, computer aided drug design, 
knowledge based design, ligand or structure based design and analogue based drug design 
(Hughes et al., 2011; Hoelder, Clarke and Workman, 2012). For this to occur via an 
analogue based approach parent compound(s) must be chosen (see chapter 3). 
Once Hit compounds are identified, secondary or confirmatory assays like dose response 
curves and counter screens are conducted to confirm the compounds preliminary activity 
(Deprez-Poulain and Deprez, 2004). Therein different routes are exploited, the hit 
compounds can undergo assays assessing bioavailability, toxicity and metabolism to hone 
in on improved hit compounds. Or the hit compounds can be investigated through a 
structure-activity relationships (SARs) approach to understand and define the key 
functional groups or regions to help a hit-to-lead optimisation phase (Katsuno et al., 2015; 
Patrick, 2017). Figure 14 provides a generic overview to the common drug discovery 
cascade from target validation to clinical drug candidate. 
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At this stage there are certain characteristics that hit compounds should possess before 
the development of lead candidates from them. Such characteristics are as follows 
(Hughes et al., 2011; Yusof et al., 2014; Katsuno et al., 2015):  
• The chemical structure of a hit should be confirmed by identification (for natural 
products) re-synthesis or re-purification. 
• Preliminary knowledge of the structure-activity relationship of a hit is desirable.  
• A Hi should exhibit a significant in vitro response with a typical IC/EC50 value 
between 5 µM-100 nM.  
• Hits should meet basic drug like profiles such as the pan-assay interference 
filters (PAINS) to prevent hits that lack target specificity. Or comply with drug 
likeness models such as the Lipinski Rule of five. 
• Counter screens should be conducted on the hit for further confirmation of its 
activity.  
• A 10-fold selective activity for cytotoxicity against the desired cell line vs 
normal mammalian cell line should be met.  
• Compounds should ideally be synthesised in fewer than five steps with no major 
synthesis or formulation issues and have an acceptable yield  
• Compounds should have suitable water/organic solubility e.g. clogp values 
between 2-3 considered optimal for a balance between cell membrane 
permeability and first pass clearance.  
Figure 14 A general process in a drug discovery programme.  
Within each stage key experimental procedures are conducted. Compound screening and secondary assays 
highlighted in red iterate the areas focused on in this research taken from (Hughes et al., 2011) 
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Lead optimisation is where lead compounds are generated with improved potency, 
reduced off target effects and enhanced pharmacokinetic properties (Bleicher et al., 2003; 
Keseru and Makara, 2006). This is carried out by modifying the existing hit compounds 
from the SAR studies. This cycle of “Hit to lead” optimisation can continue as described 
in Figure 13 until a promising lead candidate is identified (Hoelder, Clarke and Workman, 
2012). Approaches within this phase are varied, as some cycles can be focused on 
enhancing the pharmacodynamics whereas others can be improving druglikeness via 
refining the ADMET (Absorption, Distribution, Metabolism, Excretion and Toxicology) 
properties of the lead compounds. Drug design models like the Lipinski rule of five can 
be incorporated to identify the pre-clinical drug candidate (Lipinski, 2004). If successful, 
these lead candidate(s) can undergo clinical development and evaluation via phase trials 
to finally produce a licensed drug (Bleicher et al., 2003; Lipinski, 2004; Katsuno et al., 
2015). 
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1.4.2 Analogue based drug design and development 
 
Analogue drug design aims to improve the pharmacological properties of existing drugs 
or compounds. This approach is one the most common methods used in drug discovery 
(Kuntz, 1992; Shu, 1998; Sharma et al., 2009; Ghorab et al., 2016).   Flavopiridol is a 
key example in showing the success of using an analogue based drug design approach 
(Hernandes et al., 2010). Flavopiridol is a CDK2 inhibitor used to treat acute myeloid 
leukaemia. Its hit to lead conversion from an analogue demonstrates the use of functional 
group addition in improving the observed activity. L86-8276, also known as 
dechloroflavopiridol, seen in Figure 15 contains a phenyl ring next to the flavone ring. 
This particular dechlorinated analogue generates 10 van der Waals interactions within the 
ATP binding pocket of CDK2. However, Flavopridol which contains a chlorophenyl 
caused an increase in kinase inhibition by six fold. The most likely reason for this was 
that the inclusion of the chlorine caused new binding contacts within the ATP binding 
pocket, raising the number of drug to target interactions from 10 to 61 (Hernandes et al., 
2010). By replacing the phenyl with a chlorophenyl to increase binding interactions, 
Flavopiridol showed greater kinase inhibition.              
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Functional group 
addition – hit to lead 
conversion  
Figure 15 L86-8276 (dechloroflavopiridol) conversion to flavopiridol, adapted form (Hernandes et al., 2010) 
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1.5 Chemical Scaffolds as Antiangiogenic Compounds 
 
Mojzis et al. (2008) explained that much effort has been dedicated to identifying 
compounds, specifically novel chemical scaffolds, that exhibit antiangiogenic activity 
(Mojzis et al., 2008). Therein many studies have been focused on drugs that block 
extracellular matrix degradation, target endothelial cells specifically, block stimulators of 
angiogenesis, or downregulate a variety of angiogenic signalling mediators (Mojzis et al., 
2008).  
Chemical scaffolds like chalcones have been a cornerstone of drug discovery studies for 
several decades (Anto et al., 1995; Li et al., 1995; Torres-Santos et al., 1999; Balunas 
and Kinghorn, 2005; Koehn and Carter, 2005; K. Sahu et al., 2012; Zhang et al., 2013). 
Many licensed drugs to treat various conditions have been modelled from naturally 
derived chemical scaffolds (de Sá Alves, Barreiro and Fraga, 2009; Mishra and Tiwari, 
2011; Brown, Lister and May-Dracka, 2014; Rodrigues et al., 2016). In 2005, 11 out of 
the 22 FDA approved licensed antiangiogenic agents were either a natural product or were 
modelled from a natural product parent (El Sayed, 2005). Collectively, chalcones as well 
as similar structures like stilbenes and flavanoids are amongst several extensively studied 
compounds (Ratty and Das, 1988; Woods et al., 1995; Bertelli et al., 1999; Zheng and 
Ramirez, 1999; Zhishen, Mengcheng and Jianming, 1999; Tan et al., 2003; Albini et al., 
2006; Kimura, Sumiyoshi and Baba, 2008; Mojzis et al., 2008; Chahar et al., 2011; Martí-
Centelles et al., 2013; Sirerol et al., 2016).  
 
 
O
B                                  A 
Figure 16 Basic scaffold structures of chalcone. 
Chemical structure of 1,3-diphenylpropenones. 
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1.5.1 Chalcones 
 
Chalcones are a class of naturally derived compounds that are found in plants. All 
chalcones, whether natural or synthetic, consist of a 1, 3-diaryl-2-propen-1-one scaffold, 
which has been found to exhibit an array of pharmacological properties,  from anti-
microbial activities to anti-proliferative applications on leukaemic or cancer cell lines 
(Mojzis et al., 2008; Pilatova et al., 2010; Mahapatra, Bharti and Asati, 2015). The enone 
refers to the alpha beta unsaturated carbonyl region between the two phenyl rings (see 
Figure 16). Variations in functional groups and substituent positions on the aromatic rings 
have together produces hundreds of chalcone analogs. Thus, it was stated by Mahapatra 
et al (2015) that with the knowledge of molecular targets and (SARs), further phases of 
new synthesis will produce chalcones with increased efficacy and minimal toxicity 
(Mahapatra, Bharti and Asati, 2015).  
Polyphenolic chalcones are found in abundance in a range of plants, these plant extracts 
have been tested to uncover pharmacological properties (Ngameni, 2006; Detsi et al., 
2009; Batovska and Todorova, 2010; Huang, Cai and Zhang, 2010) . Within the extracts 
the active component has been the phenolic chalcone scaffold, and as a result they have 
been the initial parent design of drug discovery studies (Yang et al., 2001; Huang, Cai 
and Zhang, 2010).  
On top of this, the utilisation of synthetic methoxy based analogs have brought a variety 
of biological activities (Ethiraj, Aranjani and Khan, 2013). In 2010, Bandgar and 
colleagues reported anti-cancer, anti-inflammatory and anti-oxidant activities of simple 
synthetic methoxy based chalcones (Bandgar et al., 2010). 
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1.5.2 Reported Antiangiogenic Activities of Simple Molecular Chalcones 
 
In 2012, Lee and colleagues investigated several types of synthetic phenylpropenones 
derivatives, of which some derivatives contained heterocyclic furan or thiophene rings 
(Lee et al., 2012). Out of four derivatives the chalcone with no altered phenyl rings 
displayed the most effective inhibitory activity against VEGF-induced angiogenesis of 
HUVECs. RTK studies identified the chalcone’s ability to inhibit several RTKs including 
VEGFR-2, Tie-2, EGF, FGF and IGF-1. Mechanistic studies revealed significant 
inhibition of ERK phosphorylation and NF –kB activation. Functional analysis via a 
HT29 colon cancer cell inoculated CAM assay showed substantial inhibition of both 
tumour growth and tumour induced angiogenesis at 10 µg/ml (Lee et al., 2012).  
Lee and colleagues (2012) compared the antiangiogenic activity of diphenylpropenone 
(DPhP) with furan-2-yl-3-pyridin-2-ylpropenone (a COX-2 inhibitor reported in their 
previous studies, (E.-S. Lee et al., 2006)). Furan-2-yl-3-pyridin-2-ylpropenone (FPP-3) 
was put forward as a possible antiangiogenic drug due to its cyclooxegnase-2 selectivity, 
however in this study it was found that the diphenylpropenone could possess superior 
antiangiogenic activity then FPP-3 due its greater inhibition of VEGFR. Another 
supporting factor was DPhP significantly higher inhibition of angiogenesis in vivo of 70% 
at 5µg/CAM then FPP-3 42% at a dose of 20 µg/chick chorioallantoic membrane (CAM). 
Overall they concluded that the diphenylpropenone with no substituted phenyl rings was 
a promising candidate for further development as a antiangiogenic agent (Lee et al., 
2012).  
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Synthesised 2’5’-dihydroxychalcones by Nam and colleagues in 2003, with electron 
withdrawing group (EWG) substituents, showed overall greater cytotoxicity against 
various tumour cell lines than the same compounds with electron releasing groups (ERG). 
It was noted that the position of the EWG and the charge of the β carbon of the αβ 
unsaturated region of the chalcone were pivotal in the compounds activities. In particular, 
out of the several EWG compounds, 2-chloro-2’5’-dihydroxychalcone exhibited the 
highest selective cytotoxicity against HUVECs (table 3). The compound also displayed 
strong inhibitory effects in an vitro model of HUVEC tube formation. In an in vivo study 
with BDF1 mice bearing Lewis lung carcinoma cells at 50 mg/kg/day the compound was 
found to inhibit tumour growth by 60.5% (Nam et al., 2003).  
Table 3: 2'5'-dihydroxychalcones EC50 values against cancer cell lines and HUVECs 
With 2-chloro-2’5’-dihydroxychalcone (highlighted in yellow) showing the most selective potency towards HUVECs 
(Nam et al., 2003). 
 
 
 
 
 
 
 
 
 
 Cell Line 
B ring  B16 HCT116 A431 HUVEC 
H 2.25 3.29 2.44 1.89 
2-F 1.78 1.99 1.11 1.02 
2-Cl 1.34 1.83 0.09 0.03 
3-Cl 1.39 1.81 1.97 1.71 
4-Cl 2.18 3.62 2.16 2.01 
OH
OHCl O
Figure 17 2-chloro-2'5'-dihydroxychalcone. 
Referred to AH1 the parent compound for 
the purpose of this study (Nam et al., 2003)  
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In 2012, Varinska et al., assessed the anti-angiogenic properties of 4-hydroxychalcone 
with no additional EWG or ERG groups (Varinska et al., 2012). Selective activity was 
found on different cell lines to those used by Nam et al (2003), including human epithelial 
tumour cell line (HeLa) and activated endothelial cells (A549) (Varinska et al., 2012). In 
mechanistic studies, 4-hydroxychalcone displayed moderate activity for both VEGF and 
bFGF (Varinska et al., 2012). Induced phosphorylation by extracellular signal kinase 
(ERK)-1/2 and Akt kinase was seen. However it did not affect tumour necrotic factor 
alpha stimulated endothelial cells. Collectively this indicated that the inhibition of in vitro 
angiogenic activity was as a result of a suppression of growth factor pathways (Varinska 
et al., 2012). Results from the chick chorioallantoic membrane (CAM) assay also showed 
that 4-hydroxychalcone had inhibitory effects on bFGF driven neovascularisation 
(Varinska et al., 2012).  
 
 
 
 
Various hydroxyl based chalcones have shown promise in exhibiting antiangiogenic 
activity; in 2012, Karki synthesised 15 different hydroxychalcones with activity against 
VEGF induced angiogenesis in vivo, assessed via the CAM assay (Karki et al., 2012). 
Hydroxyl groups were in several ortho, meta and para positions on both A and B phenyl 
rings.  Structure activity relationships revealed that amongst the compounds bearing a 
single hydroxyl group on the B ring, the hydroxyl group at the para position exhibited the 
highest anti angiogenic activity of 66% at 1 µg/CAM, however only slightly more than 
HO
O
Figure 18 4-hydroxychalcone (Varinska et al., 2012) 
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the basic chalcone scaffold itself (64%). Looking into hydroxyl groups on the A ring (see 
Figure 19), 1 exerted the highest inhibition of 89% compared with dihydroxychalcones 3 
(87%) and 4 (80%) (Karki et al., 2012). This indicates that the hydroxyl group on the A 
ring resulted in superior activity than that of the B ring and the chalcone scaffold itself.  
 
 
 
 
 
2’-Hydroxy-4’-methoxychalcone displayed antiangiogenic activities in studies conducted 
by Lee et al. in 2006 (Y. Lee et al., 2006). The authors identified that this chalcone 
decreased angiogenesis in both CAM assay and the mouse matrigel plug assay (Y. Lee et 
al., 2006). Upon subcutaneous administration (30mg/kg, 20 days) to mice implanted with 
murine Lewis lung carcinoma, tumour volume was reduced by 27.2% (Y. Lee et al., 
2006). 
 
 
 
 
Cell cycle studies showed that, E-2-(4’methoxybenzylidene)-1-benzosuberone, a 
synthetic chalcone, has anti-proliferative effects via the reduced expression of anti-
apoptic gene in both Jurkat and HeLa cells (Pilatova et al., 2010). Additionally, at non-
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Figure 19 Mono and dihydroxychalcones (Karki et al., 2012) 
Figure 20 2'-hydroxy-4'-methoxychalcone (Y. Lee et al., 2006) 
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toxic concentrations the chalcone was able to inhibit VEGF-induced migration of 
HUVECs (Pilatova et al., 2010). Furthermore, decreased secretion of both MMP 
(predominantly MMP-9) and VEGF were observed (Pilatova et al., 2010). 
Molecular docking of VEGFR with quinoyl-thienyl based chalcones in one study by Rizvi 
et al. (2012), revealed that amongst their extensive series of chalcones, those with 
substituted chlorine groups at the 2 or 5 position on the thienyl ring, showed deeper 
interaction into the VEGFR ATP binding pocket, with 7-methyl-quinoyl-2’5’-
dichlorothienylchalcone (figure 21) the most potent for HUVEC cytotoxicity (Rizvi et 
al., 2012). It was also identified that all bromine derivatives were less potent, and that 
those with iodine components were deemed inactive, possibly due to the larger size 
compared to other halogens affecting their fit into the ATP binding pocket. (Rizvi et al., 
2012) 
 
 
 
 
In addition to the reported activities of hydroxylated chalcones, some methoxy derivatives 
have shown promise in inhibiting endothelial cell proliferation; for example,  Bertl et al. 
(2004) identified that 2’,2,4-trimethoxychalcone and 3-bromo-2’4’-dimethoxychalcone 
exhibited selective effects towards endothelial cell line HMEC-1, (0.15 µg/ml and 0.10 
µg/ml) and HCT116 (0.56 µg/ml and 0.38 µg/ml) (Bertl et al., 2004). 
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Figure 21 7-methyl-quinoyl,2’5’-dichlorothienylchalcone (Rizvi et al., 2012) 
Figure 22 3-bromo-2'4'-dimethoxychalcone (left) and 2',2,4-trimethoxychalcone (right) (Bertl et al., 2004) 
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2. Aims and Objectives: 
Aims: 
Nam et al. (2003) reported 2-chloro-2’5’-dihydroxychalcone had an IC50 value of 109  
nM against HUVEC cell proliferation across 3 days. This simple molecular chalcone 
displayed selectivity towards endothelial cells compared to HCT116 (colon cancer) and 
B16 (murine melanoma) cells and brought about promising antiangiogenic activity, yet 
its analogues 3 and 4-chloro-2’5’-dihydroxychalcone were inactive in comparison (Nam 
et al., 2003). It raised the question as to why this particular decoration pattern produced 
antiangiogenic activity compared to other analogues. Therefore, the aims of this 
research were to design, synthesise and biological evaluate novel classes of hydroxyl-
derivatives with 2-chloro-2’5’-dihydroxychalcone as the parent compound to: 
• better understand what components of the molecule were contributing to the 
activity observed, through structure activity relationship analyses.  
• investigate antiangiogenic activity of the hydroxyl-lead candidates via in vitro 
and mechanistic studies.  
Hypothesis:  
Change in the decoration pattern of 2-chloro-2’5’dihydroxychalcone will alter the effects 
on endothelial cell proliferation and migration, compared to the parent compound.  
Null hypothesis:  
Change in the decoration patterns of 2-chloro-2’5’-dihydroxychalcone will not alter the 
effects on endothelial cell proliferation and migration. 
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Objectives: 
To achieve this overall aim, the following objectives were put in place.  
1) Design and synthesise derivatives of 2-chloro-2’5’-dihydroxychalcone as novel 
antiangiogenic agents, using variations of the Claisen-Schmidt cross aldol 
condensation.  
2) Understand SAR of the new compounds via their effects on endothelial cell 
proliferation. This will add to the previously reported SARs to collectively give a 
better understanding of the optimal features required on a chalcone scaffold to 
exhibit anti-endothelial activity. In turn these SARs will help to identify lead 
compounds from the new analogues.  
3) Investigate the in vitro antiangiogenic functionality of the lead compounds via 
endothelial migration by using the wound healing assay.  
4) To perform mechanistic studies on the final lead compounds to delineate their 
interaction, if any, with the VEGF/VEGFR signalling pathway. 
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Chapter 3: Synthesis of chalcone 
derivatives 
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3.1 Introduction  
 
Manipulation of substituents for lead optimisation has been a widely used method, for 
fine tuning intermolecular drug-target binding interactions, in hope to increase 
pharmacological activity (Patrick, 2017).  Different approaches are used to improve 
specific characteristics, for instance phenolic groups can be used to interact with binding 
sites on protein receptor surfaces via hydrogen bonding.   
In general, functional group modifications are vital in understanding the relevance of 
specific groups on a lead compound. Analogues are made with added or removed groups 
to determine whether the specific activity is affected by such a change (Patrick, 2017). Of 
the many, halogen incorporation into the drug scaffold is very commonly used. One of 
the first uses of halogens in medicinal chemistry were to act as bulk groups in binding 
sites due to their steric effects (Hernandes et al., 2010).  Now, halogens have been used 
to stabilise protein-ligand complexes as the halogen bond can be viewed as a form of 
intermolecular interaction. This is why halogens are favourable for binding in protein-
protein interactions (Patrick, 2013). Halogenation is also a pre-requisite for compounds 
designed to pass blood the brain barrier or reach the central nervous system (Gentry et 
al., 1999; Gerebtzoff et al., 2004) 
As discussed in chapter 1 Flavopiridol and 2-chloro-2’5’-dihydroxychalcone were key 
examples of structural modification that significantly increased the desired activity. This 
formed the basis for the five series of compounds that were synthesised and tested. 
This chapter will focus on the synthesis of the compounds. The following chapter 
(Chapter 4) will discuss in more detail about the rationales of the design and anti-
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proliferative activity against HUVECs. A brief rationale as to the design of compounds 
is described in Table 4 
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Table 4 Brief rationales as to the compounds designs for this study 
Series 1 looks at replacing the chlorine group on the B ring with different functional groups. Series 2 looks at repositioning the hydroxyl groups on the A ring. Series 3 focuses on synthesising part derivatives of the AH1 
molecule. Series 4 centres around moving halogen group on the B ring to the 3 and 4 positions. Series 5 is based on synthesising methoxychalcone derivatives equivalent to the hydroxychalcones. 
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3.1.1 Synthetic approaches to chalcone synthesis  
 
Chalcones are known to exhibit a wide range of pharmacological properties (as discussed 
in Chapter 1). Therefore, it is not surprising that there are numerous approaches to 
synthesising this scaffold. Prominent examples include Suzuki Miyaura reaction, Claisen 
Schmidt condensation, Carbonylative Heck Coupling reaction and Wittig reaction 
(Climent et al., 1995; Reddy et al., 2001; Eddarir et al., 2003). These are illustrated in 
Scheme 1. The predominant and most favoured route used out of these is the Claisen 
Schmidt condensation (Climent et al., 1995). The reasons are that substituted starting 
materials (benzaldehydes and acetophenones) are readily available to order and saves 
synthesising them (minimising reaction steps). The route also uses mild conditions 
without the need of harsh or anhydrous reagents.  
 
 
 
 
 
 
 
 
Scheme 1 Different chalcone synthesis routes:  
a) Claisen-Schmidt condensation, (Smith and March, 2007); b) Suzuki-Miyaura reaction, (Selepe and Van Heerden, 
2013); c) Wittig reaction, (Xu, Chen and Huang, 1995); d) Carbonylative Heck coupling reaction, (Wu et al., 2010).  
+
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The Claisen Schmidt condensation is a cross aldol addition-condensation reaction that 
generally uses equimolar amounts of a benzaldehyde and an acetophenone in the presence 
of a base or acid catalyst (Wang, 2009). Reactions times and conditions vary depending 
on route employed and type of chalcone to be synthesised.  
For base catalysed reactions, general conditions are mostly room temperature with a short 
chain alcohol as a solvent (preferably methanol or ethanol) but addition of heat via 
classical heating or microwave irradiation can be used to drive reactions forward (Wang, 
2009). A mechanism for the base catalysed approach in Scheme 2.      
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Scheme 2 Base catalysed Claisen-Schimdt reaction mechanism 
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The first step starts off with with deprotonation of the acetophenone to form an enolate, 
although in equilibrium, it favours the enolate enough to drive the reaction forward. 
Nucleophillic attack of the enolate on the benzaldehyde’s carbonyl group occurs, forming 
the β-hydroxyketone (aldol). At this stage this intermediate compound can be isolated, 
but if left to react further, the hydroxide induced elimination of water occurs in a 
steroselective manner to form the trans alpha beta unsaturated carbonyl compound.  
There are many different variations of the base catalysed Claisen Schmidt reaction. 
Typically, sodium and potassium hydroxide are used and methanol or ethanol the solvent 
of choice. But lithium hydroxide with ethanol has been successfully used to form a variety 
of chalcone structure via a dual activation route (Bhagat et al., 2006). In which, the LiOH 
firstly provides a hydroxide source to form the enolate. Secondly, the Li+ cation combines 
with the oxygen of the aldehyde carbonyl group to form a six-membered cyclic transition 
ring. This ring causes an increase in the electrophilicity of the aldehyde carbonyl group 
making it more susceptible to nucleophilic attack by the enolate ion.   
Barium hydroxide has been used in several studies to synthesise hydroxyl-based 
chalcones (Hsieh et al., 2000; Nam et al., 2003; Kumar, Lamba and Makrandi, 2008). 
Phenolic groups under basic conditions interfere with the formation of the enolate. As a 
result there are protecting groups like tetrahydryopyranyl (THP) ethers and 
methoxymethyl (MOM) also an ether, are used to mask the phenolic groups during 
chalcone formation (Wuts, 2014). Other ether based protecting groups like tert-
butyldiphenylsilyl (TBDPS) and tert-butyldimethylsilyl (TBDMS) have also been used, 
but their instability under strong aqueous base (pH > 12) conditions requires the use 
organolithium reagents as a base with anhydrous solvents like tetrahydrofuran (THF).    
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Other approaches vary in the method and conditions used as, Stoyanov et al in 2002 
identified that microwave assisted reactions using potassium hydroxide and ethanol 
yielded a variety of different substituted chalcones in high yields. Including nitro and 
phenolic substituents without the use of protection groups (Stoyanov et al., 2002). 
Conducting these reactions in a sealed tube allows the reactions to reach temperatures 
higher than the boiling point of the solvent. These heat assisted reactions can improve 
reaction times considerably and remove the need for protective groups or anhydrous 
conditions.  
Solid state or solventless approaches have successfully yielded chalcone compounds, as 
Kumar et al in 2008 used barium hydroxide with equimolar amounts of benzaldehyde and 
acetophenone grinded in a pestle and mortar for 2-5 minutes. This was followed by ice 
cold quenching to precipitate out the chalcone. Filtration of the precipitate and subsequent 
recrystalisation via ethanol produced the desired product in yields up to 92% (Kumar, 
Lamba and Makrandi, 2008). 
For acid catalysed reactions sulphuric acid has been used as a proton source (Konieczny 
et al., 2007). In situ approaches to generate the proton source have also been looked at 
with thinoyl chloride (SOCl2), as thionyl chloride reacts with ethanol to generate and 
ethanolic solution of hydrogen chloride. Another avenue has been to use boron trifluoride 
etherate (BF3.OEt2) that functions as a Lewis acid to catalyse the reactions (Narender and 
Papi Reddy, 2007; Karki et al., 2012). A mechanism of the acid catalysed approach is 
shown in Scheme 3. 
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Scheme 3 Acid catalysed Claisen-Schimdt reaction mechanism 
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The enol tautomer of the acetophenone attacks the protonated carbonyl group of the 
benzaldehyde to generate an intermediate aldol. Protonation of the beta hydroxyl group 
of the aldol is followed by elimination of water via an E1 mechanism to generate the 
chalcone.  
Acid catalysed reactions are not as extensively used when compared with base catalysis 
for chalcone synthesis. But there are still several routes that successfully yield a variety 
of chalcones. Phenolic chalcones are heavily investigated for their pharmacological 
properties and this approach can be very useful for synthesising them, as under these 
conditions protecting groups of phenolic substituents are not required and reduces the 
need for additional steps in the overall reaction (Batovska and Todorova, 2010; Orlikova 
et al., 2011).   
The use of boron trifluoride etherate (BF3.OEt2) with 1,4-dioxane has yielded many types 
of which bear hydroxyl, nitro, halo and methoxy substituents (Narender and Papi Reddy, 
2007; Karki et al., 2012). However, as BF3O readily reacts with water in the air, reactions 
must be carried out under anhydrous conditions. 
Chalcones synthesised using thionyl chloride approach can be carried out without the 
need of an inert atmosphere and has also successfully produced different substituted 
chalcones, including hydroxyl and nitro groups. These are generally difficult to synthesise 
under basic conditions (Petrov, Ivanova and Gerova, 2008).    
Sulphuric acid as a proton source has been used to yield chalcone derivatives. A 
combination of sulphuric acid with acetic acid as a solvent has been used to produce 
oxathiolone fused chalcones (Konieczny et al., 2007). The oxathiolone ring was deemed 
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more favourable due to its flexibility than Konieczny (2007) and colleagues previous 
work on aurone derivatives, which are fixed in a flat planar configuration.  
All the chalcones synthesised in this project were carried out using variations of the 
Claisen Schmidt condensation. Reactions were carried out and chalcones were verified 
using NMR, MS, FTIR-ATR instruments.  
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3.2 Results and Discussion: 
The code AH was used as a prefix to code each compound synthesised e.g. AH1. 
3.2.1 Base catalysis for hydroxychalcone synthesis with THP protection step  
 
For hydroxyl based chalcones, the Claisen Schmidt base catalysed reaction with THP 
protection was the initial route of choice, as polyphenolic groups hinder enolate formation 
under normal basic conditions.  This was the same route used by Nam et al (2003) to 
synthesise their 2’5’-dihydroxychalcones (Nam et al., 2003). The scheme of how the THP 
group is used is shown in Scheme 4 below.   
R
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Scheme 4 Method 1 of synthesising dihydroxychalcones (Nam et al., 2003) 
Reagents and conditions: (a) pyridinium-p-toulenesulphonate, 3-4-dihydro-2H-pyran, anhydrous DCM, r.t. (b) aryl 
aldehyde, barium hydroxide octahydrate, MeOH, 18hr, r.t. (c) pyridinium-p-toulenesulphonic acid, MeOH, 2hr, r.t.  
The general procedure for this route was as follows. The dihydroxyacetophenone 1 was 
dissolved in DCM with pyrindium-p-toluene sulfonate (ppts) followed by 3-4-dihydro-
2H-pyran. The residue yielded crude protected-acetophenone 2. The crude protected-
acetophenone 2, barium hydroxide octahydrate and benzaldehyde were dissolved in 
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methanol and left to stir for 24 hours. This yielded crude protected hydroxychalcone. The 
protected chalcone 3 and p-toluenesulfonic acid were dissolved in methanol for 4 hours. 
This yielded the crude deprotected chalcone 4 which was purified by recrystalisation from 
ethanol or propan-2-ol or by flash column chromatography.   
AH9, AH10, AH11, AH15 and AH19 were synthesised using the above procedure and 
verified using NMR, FTIR, MS and HPLC (see Table 5). 
Coupling constants of the alkene protons via NMR provides a way to distinguish between 
cis and trans configurations, as trans give slightly higher values of 12-18Hz compared to 
5-14Hz of cis. The trans-chalcone configuration was confirmed by the larger coupling 
constants (between 15-18 Hz) see experimental section 8.2.3.2. This was seen as a 
characteristic two one proton doublets (see figure 23). Secondly the deshielded phenolic 
protons were seen far downfield (11-15ppm). 
For FTIR-ATR, hydrogen bonding of the carbonyl group with phenolic group in A ring 
ortho position resulted in lower frequency absorption via reduction in double bond 
behaviour (Williams and Fleming, 1995). This was seen with many of the phenolic 
chalcones IR spectras bearing A ring 2-position hydroxy groups as the carbonyl peak 
values were between 1639-1643cm-1 (only AH12 showing a higher value of 1647 cm-1) 
which is collectively lower than the standard αβ unsaturated carbonyl peak value between 
1685-1665cm-1.  
Purity of each compound was validated using HPLC. All compounds showed purity 
above 95% which was an agreed pre-requisite in order for them to be biologically tested 
in vitro. Figure 24 shows an example of a dihydroxychalcone in MeOH solution ready 
for UV-VIS analysis, in order to obtain the lambda max needed to run the sample via 
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HPLC (using a UV-VIS detector). HPLC spectra of AH9 illustrates the “one peak” 
representing the one pure compound in the sample.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 23 Characteristic two one proton doublets 
with a large coupling constant (12-18 Hz) found for 
the trans chalcone configuration 
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A 
Figure 24 (A) AH9 in EtAc solution. (B) UV-vis spectra of AH9 showing lambda max = 308nm. (C) AH9 HPLC spectra conducted at the 
lambda max 308 gathered by UV-VIS.  
C 
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Table 5 Compounds synthesised via method 1 
These compounds were purified via recrystalisation from ethanol. 
Compound Ar (B-ring) Ar’ (A-ring) Yield (%) m.p (oC) 
AH9 2-Br-C6H4 2,5-(OH)2C6H3 35 177-179 
AH10 2-(CH3)C6H4 2,5-(OH)2C6H3 26 174-179 
AH15 2-Cl-C6H4 2,4-(OH)2C6H3  127-130  
AH11 2-F-C6H4 2,5-(OH)2C6H3 26 192-194 
 
AH1, AH8 and AH13 were also synthesised via this procedure but did not recrystalise 
out from flash column chromatography was used (see Table 6). TLC analysis of the final 
crude mixture for these reactions showed multiple similar polarity spots. Staining the 
TLC plate with 2-4-diphenylhydrazine to visualise the spots containing a carbonyl groups 
but it was the visible yellow colour of the chalcone (due to conjugation) that allowed us 
to identify it amongst the others. Comparing the TLC plates of the protected chalcone 
mixture vs the deprotected mixture showed that separating out the protected chalcone 
would be more appropriate given the gap in Rf values between the chalcone, 
benzaldehyde and aldol. Therefore the protected chalcone was isolated via column 
chromatography leaving deprotection to yield pure hydroxychalcone.  
Table 6 Compounds synthesised via method 1 continued 
These compounds were purified via flash column chromatography. 
 
Compound Ar (B-ring) Ar’ (A-ring) Yield (%) m.p (oC) 
AH1 2-Cl-C6H4 2,5-(OH)2C6H3 21 187-189 
AH8 2-(OC2H5)C6H4 2,5-(OH)2C6H3 60 89-91 
AH13 2-(OCH3)C6H4 2,5-(OH)2C6H3 14 146-149 
AH2 3-Cl-C6H4 2,5-(OH)2C6H3 52 168-170 
AH3 4-Cl-C6H4 2,5-(OH)2C6H3 22 187-188 
AH4 3-Br-C6H4 2,5-(OH)2C6H3 42 152-144 
AH5 4-Br-C6H4 2,5-(OH)2C6H3 17 188-189 
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NMR analysis of both AH8 and AH13 confirmed the presence of the compound with 
very similar spectras in the aromatic regions. Both possess an alkoxy group on the B ring 
ortho positions thus proton splitting patterns were similar. The marked difference was 
that with AH8 the CH3 protons of the ethoxy group contributed to the triplet seen in the 
aliphatic region of 1.44ppm. The CH2 protons contributed to the quartet which was seen 
more downfield (4.17ppm) in comparison due to the neighbouring electronegative 
oxygen group. Whereas for AH13, a singlet was seen at 3.92 ppm corresponding to the 
CH3 having no neighbouring protons.  
Synthesis of AH12 (2-nitro-2’5’-dihydroxychalcone) was attempted via this route, but 
TLC analysis during the chalcone reaction stage revealed no product formation and only 
the presence of the two starting materials. This agreed with the findings of Nam et al in 
2003, as they could not synthesise a nitro-dihydroxychalcone via this route due to the 
strong electron withdrawing nature of the nitro group hindering aldol formation (Nam et 
al., 2003). Therefore the reaction was abandoned and another approach was used.  
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3.2.2 Base catalysis for hydroxychalcone synthesis under pressurised conditions 
 
In an attempt to improve yields of the compounds synthesised (via the THP route) and to 
minimise the steps required, different conditions were looked at.  
This sets of conditions utilised a conventional base catalysed reaction (KOH) and ethanol 
but in a sealed tube heated up to 132oC for several minutes in an oil bath (Stoyanov et al., 
2002). Stoyanov (2002) reported 3 minutes was enough to ensure reaction completion 
and any further would have caused cyclisation to the dihydroflavone, which is illustrated 
in scheme 5 below (Stoyanov et al., 2002). AH9 was used as a model reaction. 
 
Scheme 5 Cyclisation of the 2'5'-dihydroxychalcone to a hydroxyl-dihydroflavone if left to react further under 
the KOH/EtOH reaction conditions in a sealed tube (Stoyanov et al., 2002). 
Reagents and conditions: (a) KOH, EtOH - µW or 132oC 
a
R
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Several reactions were carried out at with different reaction times to assess at what time 
flavone formation occurs. Despite Stoyanov and colleagues stating that no flavone would 
be produced after 3 minutes, the TLC analysis showed both chalcone and potential 
flavone formation. Shorter times showed starting materials and longer durations showed 
decomposition and minimal chalcone formation. Some chalcone was isolated but only 
afforded enough for proton NMR analysis.  
Therefore due to the breath of resources (silica and solvents) required to just afford 
enough 4-5mg the reaction was deemed unfeasible for multiple chalcone syntheses and 
thus other avenues were explored.  
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3.2.3 Acid catalysis for hydroxychalcone synthesis using thionyl chloride 
 
This acid catalysis route consisted an ethanolic solution of hydrogen chloride generated 
from thionyl chloride and ethanol. Initially, investigation into the synthesis of a 
monohydroxy analogue was first looked at to see if this could be synthesised, as Petrov 
(2008) reported successful synthesis of 4-hydroxychalcone (Petrov, Ivanova and Gerova, 
2008). AH16 (2-chloro-4’-hydroxychalcone) was reacted using the following protocol. 
Equimolar quantities of the acetophenone and benzaldehyde were dissolved in ethanol 
followed by dropwise addition of thionyl chloride (1.6eq) and allowed to react overnight. 
Quenching with water induced a precipitate. TLC analysis confirmed chalcone formation 
which was further verified by NMR and MS.  
Table 7 Compound synthesised via the acid catalysis route using thionyl chloride 
This compound were purified via recrystalisation by ethanol. 
 
 
This route synthesised AH16 and yielded 25%. The route was then used to try and 
synthesise AH12. Sticky residue was apparent after quenching, TLC analysis showed 
baseline decomposition and no indication of any chalcone formation. Repeating the 
reaction with 10x the amount of thionyl chloride was attempted but no improvement in 
reaction progression was seen. As a result, this approach was stopped and another route 
was considered.   
 
 
 
Compound Ar (B-ring) Ar’ (A-ring) Yield (%) m.p (oC) 
AH16 2-ClC6H4 4-(OH)C6H3 25 167-169 
93 
3.2.4 Acid catalysis for hydroxychalcone synthesis using sulphuric acid.  
 
As the thionyl chloride or pressurised routes did not successfully yield 
dihydroxychalcones another route was looked at. The route involved the use of sulphuric 
acid as the proton source coupled with acetic acid as the solvent (Konieczny et al., 2007).  
       Reagents and conditions: (a) CH3COOH, H2SO4, 80oC, 18hr.  
 
The general procedure is as follows. Equimolar quantities of the acetophenone and 
benzaldehyde were dissolved in acetic acid followed by dropwise addition of conc 
sulphuric acid. The reaction was stirred at 80oC until reaction completion. AH12 was 
attempted via this route, TLC analysis after several hours of reacting showed presence of 
the chalcone but that it was co running with the acetophenone in the mixture. After 
allowing the reaction to occur for several days, no improvement in furthering the reaction 
was seen. The co-running spots would cause difficulty in purification, therefore repeating 
the reaction with a slight modification was carried out. This reaction used a slight excess 
of benzaldehyde (1:1.1 ratio) to ensure that all the acetophenone would be used up. After 
24 hours of reacting TLC analysis showed only chalcone formation and benzaldehyde but 
no acetophenone. On top of this solid precipitate was formed, recrystalisation from 
2
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Scheme 6 Method 2 of synthesising dihydroxychalcones (Konieczny et al., 2007) 
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ethanol afforded the chalcone with 27% yield. Monohydroxychalcones (AH17 and 
AH17a) was also successfully synthesised via this route.  
This route was used to synthesise a nitro-dihydroxychalcone without the use of protecting 
steps or anhydrous/aprotic conditions in a one pot synthesis approach. For structure 
determination of AH12, FTIR-ATR identified NO2 peaks at 1345 and 1517 cm-1 along 
with the C=O (1647 cm-1) and OH (3396 cm-1) peaks.  
Due to the success of this route of reaction, AH1 was resynthesised via this route in an 
attempt to improve the yield of the parent compound without using additional protection 
steps. Only a slight improvement in yield was seen.   
Table 8 Compounds synthesised via the acid catalysis route using sulphuric acid. 
These compounds were purified via recrystalisation by ethanol. 
 
 
 
 
To add, resynthesis of AH8 and AH13 via this route were unsuccessful. This suggested 
that the route is favourable to certain substituted dihydroxchalcones. But further testing 
is required to explore this hypothesis.  
 
 
 
 
Compound Ar (B-ring) Ar’ (A-ring) Yield (%) m.p (oC) 
AH12 2-NO2-C6H4 4-(OH)C6H3 25 190-192 
AH1 2-Cl-C6H4 2,5-
(OH)2C6H3 
29 187-189 
AH17a 2-Cl-C6H4 2-(OH)C6H3 18 77-81 
AH17 2-Cl-C6H4 3-(OH)C6H3 20 112-115 
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3.2.5 Base catalysis for methoxychalcone synthesis  
 
A base catalysed Claisen-Schmidt condensation was used to yield the non-hydroxyl based 
chalcones. A few different combinations of base with MeOH or EtOH were attempted, 
for instance 50% aq NaOH with MeOH, 10eqv Ba(OH)2 with MeOH and LiOH with 
EtOH (Bhagat et al., 2006; Kumar, Lamba and Makrandi, 2008). But the most efficient 
route with the highest yields was using 20% aq KOH with EtOH for these halogenated 
dimethoxy derivatives (Detsi et al., 2009).  
 
 
 
 
 
  
 
            Reagents and conditions: (a) EtOH, 20% KOH (aq), RT, 18hr. 
 Table 9 Compounds synthesised via the base catalysis route using either NaOH, LiOH or Ba(OH)2. 
These compounds were purified via recrystalisation by ethanol. * = 2nd standard compound from (Bertl et al., 2004). 
 
 
 
 
 
 
 
Compound Ar (B-ring) Ar’ (A-ring) Yield (%) m.p (oC) 
AH21 2-Cl-C6H4 2,5-(OCH3)2C6H3 55 88-92 
AH21a 2-Cl-C6H4 2,6-(OCH3)2C6H3 56 132-139 
AH21b 2-Br-C6H4 2,5-(OCH3)2C6H3 88 100-102 
AH21c 2-Br-C6H4 2,6-(OCH3)2C6H3 61 159-160 
AH22 2-Cl-C6H4 2,4-(OCH3)2C6H3 67 112-115 
AH22a 2-Br-C6H4 2,4-(OCH3)2C6H3 81 123-125 
AH22b 3-Cl-C6H4 2,4-(OCH3)2C6H3 81 123-125 
AH22s2* 3-Br-C6H4 2,4-(OCH3)2C6H3 80 89-90 
AHXRS1 2-Cl-C6H4 C6H3 91 52-54 
Scheme 7 Method to synthesise dimethoxychalcone (Detsi et al., 2009) 
Method 3
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Structure determination by NMR confirmed the chalcones were synthesised. As along 
with the characteristic alkene protons and aromatics between 6-8ppm, the methoxy 
protons were apparent as singlets around 3.9ppm just after the water peak (3.4ppm) of the 
deuterated DMSO solvent.  
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3.3 Conclusion 
 
Dihydroxychalcone derivatives (AH1, AH2, AH3, AH4, AH5, AH8, AH9, AH10, 
AH11, AH13 and AH15) were synthesised successfully using the base catalysed Claisen-
Schmidt condensation with THP protection step. AH12 could not be synthesised via this 
route, due to the strong EWG nature of the nitro group hindering enolate formation. 
Different base catalysed conditions were looked at including: heating the reaction to 
132oC in a sealed tube and grinding the starting materials in a pestle and mortar. Both 
reaction methods were unsuccessful in yielding AH12.  
Acid catalysed routes were also looked at. At first, in situ formation of the proton source 
via thionyl chloride and EtOH was attempted, AH16 a monohydroxy derivative was 
synthesised successfully (yield 25%) but in this study dihydroxychalcones synthesis via 
this route were all unsuccessful despite reports of this in literature (Jayapal, Sreenivasa 
Prasad and Sreedhar, 2010). The use of sulphuric acid as an acid catalyst with acetic acid 
as a solvent successfully yielded a nitro-dihydroxychalcone (AH12, 25%) in a one pot 
procedure. This was otherwise unable to be made with the conventional THP protection 
base catalyse route. AH1 was also made via this route and yielded a slightly more than 
the THP protection route (29 % to 21%). However given that multiple steps were needed 
for the protection route, when compared to the one pot synthesis via sulphuric acid/acetic 
acid route, the reduction in synthetic steps could be seen as an improvement in the 
synthesis of AH1.  
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Chapter 4: Screening and biological 
evaluation of the synthesised 
chalcone derivatives 
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4.1 Introduction:  
 
Proliferation assays conducted on endothelial cells are a common way to screen 
compounds to identify lead candidates with possible antiangiogenic activity (Nam et al., 
2003). A cell-based screening process was carried out against the synthesised chalcone 
derivatives to assess anti-proliferative activity of the compounds towards HUVECs as 
well as understanding how changes in substitution patterns affect the anti-endothelial 
activity observed. The main aim of this piece of work was to identify lead compounds of 
interest to further test from.   
HUVECs are seen as one of the common endothelial cell models to assess angiogenesis 
due its primary origin and ease of cell isolation (Staton, Lewis and Bicknell, 2007), as a 
result they are a widely accepted model (Morales et al., 1995; Tsujii et al., 1998; Ridgway 
et al., 2006; Zhong et al., 2012; Su et al., 2016).  
Several types of proliferation assays are used to assess drug induced cytotoxicity. Some 
use variations of tetrazolium salts like WST-1, XTT and commonly used MTT. The MTT 
assay measures the colourmetric conversion of a yellow water soluble dye to an insoluble 
purple formazan product which is catalysed by mitochondrial dehydrogenases in viable 
cells, this is demonstrated in figure 25 (Denizot and Lang, 1986). The MTT reagent is 
positively charged and can easily penetrate cells, whereas the WST-1 and XTT are 
negatively charged and require an intermediate electron acceptor in order to penetrate 
cells (Riss et al., 2004). This is one the reasons why the MTT assay is more commonly 
used. The absorbance measured (560nm) via spectrophotometry is proportional to the 
number of living cells present (Denizot and Lang, 1986). Therefore this assay can be used 
for assessment of both endothelial cell viability and cell proliferation, as a result it was 
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the assay of choice for this study (Mosmann, 1983; Denizot and Lang, 1986). The 
preliminary screening process comprises of using one concentration of each drug, 
allowing for quick identification of potential lead candidates for further pharmacological 
analysis.  
 
 
 
 
 
 
 
Several drug discovery studies have used this approach of a single concentration screen. 
Cabrera and colleagues  (2007) adopted a one concentration method to screen a group of 
chalcones, flavones and flavanones. A 10 µM screen was utilised by Bandgar et al 2010 
to elucidate lead candidates from a library of simple methoxylated chalcones.  (Cabrera 
et al., 2007; Bandgar et al., 2010; Dias et al., 2013). To identify lead compounds from a 
libray of chalcones and flavanols, Dias and colleagues (2013) used a 15 µM screen.   
Early screening assays generally use concentrations within 1-10 µM to identify possible 
lead candidates (Hughes et al., 2011). The lead compounds EC50 concentrations usually 
fall within the range of 100 nM - 5 µM (Hughes et al., 2011; Yusof et al., 2014). This is 
one of the “HIT” criteria mentioned in Chapter 1.4.1. As discussed in Chapter 3, AH1 (2-
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Mitochondrial Reductase 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
MTT (yellow water soluble) 
 
(E,Z)-5-(4,5-dimethylthiazol-2-yl)-1,3-diphenylformazan 
Formazan (purple water insoluble) 
 Figure 25 Chemical structures of the MTT reagent and Formazan product.  
The MTT reagent in reduced by the mitochondrial reductase to form the purple formazan product. This can only be 
carried out by living cells and therefore is used a measure to assess cell viability and cell proliferation.  
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chloro-2’5’-dihydroxychalcone) was the parent compound used for this study of which 
the synthesised compounds have been modelled from (Figure 26).  
 
 
 
 
Intially a preliminary three concentration screen was carried out at 100 µM 10 µM and 1 
µM. Compounds at 100 µM displayed potent activity with little variations in effects 
between the compounds suggesting the 100 µM was too concentrated. At 1 µM anti-
proliferative activity was minimal with again very little discrepenacies between the 
compounds, suggesting too dilute of a concentration. But at 10 µM there was clear 
differences in activity to conduct Quantitative structure activity relationships (QSARs) 
and thus it was the chosen concentration to take forward. EC50 of these lead candidates 
were evaluated (Yusof et al., 2014). Three day incubation of the drugs was used for all 
anti proliferative studies (both preliminary and main experiments) to allow for 
comparison with the parent compound data, as Nam et al (2003) performed their 
experiments across 3 days allowing time for cell proliferation to occur.  
 
 
 
OH
OH
Cl O
AH1  
Figure 26  Chemical structure of AH1 (2-chloro-2'5'-
dihydroxychalcone). The parent compound for this study. 
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4.2 Results and discussion:  
4.2.1 Anti-proliferative activity:  
 
Following, is a report of the rationales for the groups of compounds synthesised and the 
data gathered for each of them with structure activity relationship analyses. This is 
followed by a table representing the percentage reduction in HUVEC viability ± SEM at 
10 µM for each particular series.  
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4.2.1.1 Substituent changes of the B ring 2 position to assess the importance of the 
chlorine group in AH1 (series 1) 
 
As discussed in Chapter 1.5.2 studies by Nam and colleague antiangiogenic activity of 2-
chloro-2’5’-dihydroxychalcone (AH1) was greatly dependent on the positioning of the 
chlorine group on the benzaldehyde ring (B ring) (Nam et al., 2003). Therefore this group 
of compounds was developed to better understand the importance of the B ring 2-position 
by synthesising various 2-positioned substituted 2’5-dihydroxychalcones. For instance, a 
methyl group was used to assess if bulking the 2 position would cause significant activity. 
Bromine substitution was put in to see if an increase in size of the atom with similar 
electronegativity could cause an increase in activity. Stronger EWGs such as a nitro group 
were employed to see if further reducing the electrophilicity of the β carbon would 
contribute to more potent activity. In comparison, ERGs like methoxy and ethoxy were 
used to assess what affect they would have at the ortho position specifically compared to 
the parent compound and other EWG analogues. 
Within this series of dihydroxychalcones, anti-proliferative activity was greatly 
influenced by the functional group at the B ring 2 position, as hypothesised. The parent 
compound AH1 exhibited 95% ± 1.64 reduction in HUVEC viability at 10 µM, AH9 also 
exhibited potent activity (79.62% ± 4.45). This indicated that the bromine group was 
showing similar effects to the chlorine group in exhibiting the anti-endothelial activity 
observed at that position. AH11, bearing the fluorine group, showed weaker activity 
(67.96% ± 2.47) compared to AH1 and AH9 but still higher than the unsubstituted 2-
position 2’5’-dihydroxychalcone (AHXRS3, see series 3). This is line with the studies 
conducted by Nam et al (Nam et al., 2003). Fluorine is the most electronegative halogen, 
but occupies the same size in space as hydrogen. Given that chlorine and bromine are less 
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electronegative but larger in size, points towards the size of the substituent being an 
important factor in the activity observed at the 2-position. This links back to Cheng et al 
2010 hydroxyaurone study, as they concluded that the size and shape of the substitute 
group was more important than the electronegativity at least in terms of anti-proliferative 
activity against HUVECs (Cheng et al., 2010). 
When assessing the importance of electronegativity, both alkoxy ortho (AH8 and AH13) 
derivatives displayed lesser activity (56.86% ± 6.90, 49.29% ± 7.47) upon affecting 
HUVEC viability compared to AH1. Both –OMe and –OEt are ERG in the 2 position 
compared to –Cl (AH1) and –Br (AH9) which are weakly EWG (also in the 2 position).  
The results of the changes in electronegativity were in accordance to Nam et al 2003 
findings of EWG groups on the B ring being more favourable to cause cytotoxicity to 
HUVECs. AH10, an alkyl derivative, used as a substituent to increase lipophilic 
interactions and as a bulking agent showed reduced activity by 44% (50.09% ± 3.82) 
when compared with AH1. AH12 bearing a strong EWG of –NO2 at the 2 position 
showed strong anti-proliferative activity at 10 µM (87.33% ± 2.77), similar to AH1 and 
AH9. This strongly reinforced, the view that Nam and colleagues had, that increasing the 
electrophilicity of the β carbon via EWG on the B ring (Nam et al 2003) would increase 
anti-proliferative activity, especially when compared to the ERGs on AH8 and AH13.  
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Compound Structure  Reduction in HUVEC 
viability a,b ± SEM 
AH1 
 
94.94 ± 1.64 
AH8 
 
56.86 ± 6.90 
AH9 
 
79.62 ± 4.45 
AH10 
 
50.09 ± 3.82 
AH11 
 
67.96 ± 2.47 
AH12 
 
87.33 ± 2.77 
AH13 
 
49.29 ± 7.47 
OH
OH
Cl O
OEt
OH
OHO
OH
OHBr O
OMe OH
OH
OH
OHF O
NO 2 OH
OH
O
OMe OH
OH
O
a = Values are means ± SEM of four independent experiments. Data expressed as a % vs untreated control. 
b = Compound administered at 10 µM concentrations. DMSO 0.1% was used as a normalisation control. 
 
Table 10 Summary of structure and biological activity for Series 1 
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4.2.1.2 Position changes of the A ring hydroxyl groups to assess the importance of 
2’5’-dihydroxy moiety of AH1 (series 2) 
 
From the study by Nam et al (2003), it was evident that the ortho positioned chlorine 
group on B ring was important for the activity observed. But no real investigation was 
carried out to assess the importance of the 2’5-dihydroxy A ring moiety. Thus this series 
was designed to assess the importance of this, by varying the substitution patterns.  
Repositioning the hydroxyl groups to a 2’4’-dihydroxy A ring was looked at to form 
AH15. Mono equivalents in ortho and para positions were synthesised to investigate 2-
chloro-monohydroxy activities compared to the parent compound.  
From the anti-proliferative data, we found that moving the hydroxyl group from 5’-
position to the 4’-position (i.e. AH1 to AH15) reduced the activity by 30%. A similar 
result was obtained when the 5’-hydroxy group was removed as in AH17a (56.67% ± 
2.70). This was first suggesting that there is importance of the 2’5’-dihydroxy moiety 
specifically that orientation over the 2’4’-dihydroxy. Secondly, the fact that AH17a 
bearing the 2’positioned-hydroxyl group only showed weak activity in relation to AH1, 
suggests that the ortho-hydroxyl group alone was not sufficient to cause activity. To add 
AH16 bearing only a single hydroxyl groups in the 4’-positions exhibited 55% but 
moving the hydroxyl group to the 3’ position, AH17, reduced the activity to 15%. This 
was suggesting that the 3’-positioned hydroxyl group was unfavourable for exhibiting 
anti-proliferative activity. This further supports the importance of the 2’5’-dihydroxy 
moiety on the A ring specifically in relation to the anti-proliferative activity of AH1 
towards HUVECs.  
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Compound Structure Reduction in HUVEC 
viability a,b ± SEM 
AH15 
 
61.00 ± 1.78 
AH16 
 
54.79 ± 1.92 
AH17 
 
15.35 ± 4.39 
AH17a 
 
56.67 ± 2.70 
a = Values are means ± SEM of four independent experiments. Data expressed as a % vs untreated control. 
b = Compound administered at 10 µM concentrations. DMSO 0.1% was used as a normalisation control. 
 
OH
OHCl O
OH
Cl O
OH
Cl O
OHCl O
Table 11 Summary of structure and biological activity for Series 2 
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4.2.1.3 Assessing part derivatives of AH1 to see what substituents are key to the 
activity observed (series 3)  
 
Another approach was used here to focus on the parent compound itself by identifying 
active components of the 2-chloro-2’5’-dihydroxychalcone molecule (AH1). This was 
done by synthesising part derivatives of the parent compound as seen in Table 8 to see 
the importance of the second phenyl ring but keeping the alpha beta unsaturated ketone 
moiety and chlorophenyl in place. This would help determine at what point does the 
observed activity drop off and therefore help in determining the components responsible 
for the antiangiogenic activity observed. The following XRS suffix refers to the 
compounds that were designed as part derivatives of AH1 in this particular series.  
It was interesting to see for AHXRS1 that removing the 2’-hydroxyl from AH17a does 
not reduce activity i.e. both exhibiting similar inhibitory activities (56% and 57%). 
AHXRS1 showed no improved anti-proliferative effect towards HUVECs compared to 
AH17a. To add AHXRS3 showed less activity compared to AH1 (82% reduction), this 
is in line with the findings Nam an colleagues concluded in their study (Nam et al., 2003). 
This further proves that the 2’5’-dihydroxy moiety alone is not sufficient enough to cause 
potent anti-proliferative activity against HUVECs. Collectively for this particular series 
the SARs data showed that yes the ortho chlorine group on the B ring is important, but 
only in conjunction with a dihydroxy moiety on A ring specifically for maximum anti-
endothelial effect on HUVECs.  
Between the AHXRS compounds it was remarkable to see that between AHXRS3 and 
AHXRS4 there was only a slight difference in activity (13% to 21%). But when 
comparing AHXRS1 and AHXRS4, AHXRS1 showed greater reduction in HUVEC 
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viability than AHXRS4 (50% to 21%). Collectively, this further supports the concept that 
the ortho-chlorine group on the B ring contributes more to the overall activity of AH1 
than the 2’5’-dihydroxy moiety.  
Looking back on the work of Lee et al 2012 on antiangiogenic diphenylpropenones, they 
reported similar activity for AHXRS4 against HUVECs using the same cell viability 
assay (Lee et al., 2012). What is clear is that modifying the parent compound AH1 does 
alter the activity observed. This rejects the null hypothesis first proposed in Chapter 2 
which was that changing the decoration pattern of AH1 would not alter the anti-
endothelial activity.  
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Compound Structure Reduction in HUVEC 
viability a,b ± SEM 
AH1 
 
94.94 ± 1.64 
AH17a 
 
56.67 ± 2.70 
AHXRS1 
 
50.14 ± 10.11 
AHXRS3 
 
13.62 ± 8.07 
AHXRS4 
 
21.87 ± 8.25 
OH
OHO
a = Values are means ± SEM of four independent experiments. Data expressed as a % vs untreated control. 
b = Compound administered at 10 µM concentrations. DMSO 0.1% was used as a normalisation control. 
 
Table 12 Summary of structure and biological activity for Series 3 
Cl O
OHCl O
OH
OH
Cl O
O
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4.2.1.4 Position changes of the halo group on the B ring to further confirm the 
importance of the halo group at B ring 2 position (series 4)  
 
After establishing the importance of 2-chlorophenyl in the activity of AH1 over the 2’5’-
dihydroxy moiety, the next phase was look 3 and 4 positioned halogenated derivatives. 
As AH11 (2-fluoro-2’5’-dihydroxychalcone) did not exhibit significant activity and AH9 
(2-bromo-2’5’-dihydroxychalcone) did, only chlorinated and brominated derivatives 
were synthesised and not fluorinated. This series was also put together to re confirm the 
finding of Nam et al and colleagues as they concluded that 3-chloro, 4-chloro and 4-
bromo-2’5’-dihydroxychalcone did not show significant activity compared to 2-chloro-
2’5’-dihydroxychalcone (AH1) as highlighted earlier (Nam et al., 2003). 
All 3 and 4 positioned derivatives (AH3, AH4, AH4 and AH5) showed lesser activity 
than that of AH1 and AH9. This helps to prove that for AH1 and AH9 the positioning of 
the halophenyl in the 2-position was important to the anti-proliferative activity found. 
At the 2 and 4 positions on the B ring both inductive and resonance effects are operating, 
but at the 3 position only inductive effects occur. To add, at the 2 position steric influences 
i.e. the size of the substituent are also a key factor. Therefore having established that for 
these particular compounds, the steric effects at the 2 position maybe contributing more 
to the anti-proliferative activity than the inductive and resonance effects that are also 
operating.  
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Compound Structure Reduction in HUVEC 
viability a,b ± SEM 
AH1 
 
94.94 ± 1.64 
AH2 
 
45.23 ± 12.70 
AH3 
 
66.23 ± 3.20 
AH9 
 
79.62 ± 4.45 
AH4 
 
67.11 ± 4.98 
AH5 
 
68.40 ± 1.57 
OH
OH
Cl
O
OH
OH
Cl
O
OH
OH
Br
O
OH
OH
Br
O
a = Values are means ± SEM of four independent experiments. Data expressed as a % vs untreated control. 
b = Compound administered at 10 µM concentrations. DMSO 0.1% was used as a normalisation control. 
 
OH
OHBr O
OH
OH
Cl O
Table 13 Summary of structure and biological activity for Series 4 
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4.2.1.5 Replacement of hydroxyl groups with a methoxy group to assess the 
importance of hydrogen donation on the A ring (series 5)  
 
Collectively so far SARs studies have shown the important of the 2’5’-dihydroxy moiety 
for AH1 and AH9. To assess whether the activity observed is due to hydroxyl groups 
acting as hydrogen acceptors or donors the following methoxy equivalents of AH1 and 
AH9 were evaluated.  
Hydrogen groups can function as both hydrogen bond donors and acceptors. Methoxy 
groups can only act as hydrogen acceptors because they lack a hydrogen. Masking the 
hydroxyl groups as the methyl ether helps us to identify if they are functioning as 
hydrogen bond donors. Methoxy groups are larger than hydroxyl groups and less electron 
releasing via resonance (in the ortho and para positions). The inductive effect is the same 
as a hydroxyl group also.  
Interestingly the methoxy analogues showed potent anti-endothelial activity in relation 
to their hydroxyl counterparts at 10 µM. This could suggest that the hydrogen donating 
capabilities of the hydroxyl groups are not imperative to exhibit the activity seen. This 
means that the methoxy groups with their hydrogen accepting ability were able to cause 
significant reduction in HUVEC viability. Having the methoxy groups on the chalcone 
increases lipophilicity which would increase permeability across the cell membrane. 
Therefore the potent activity could be due to the increased lipophillicity allowing the 
compound to enter the cell better, to invoke an anti-proliferative effect. Whether the 
activity seen, was due to a combination of the hydrogen donating ability and increased 
lipophillicity requires further research.   
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Regarding methoxychalcones, as discussed in Chapter 1, Bert et al (2004) reported 
nanomolar IC50 value concentrations of 3-bromo-2’4’-dimethoxychalcone against 
HMECs. Although upon a microvascular endothelial cell line (using a different 
cytotoxic assay), it was interesting to see related structures in this piece of work possess 
high anti-proliferative activity against an endothelial cell also.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
115 
 
 
Compound Structure Reduction in HUVEC 
viability a,b ± SEM 
AH1 
 
94.94 ± 1.64 
AH21 
 
86.03 ± 3.26 
AH21a 
 
85.32 ± 2.27 
AH9 
 
79.62 ± 4.45 
AH21b 
 
84.72 ± 4.56 
AH21c 
 
62.79 ± 9.47 
a = Values are means ± SEM of four independent experiments. Data expressed as a % vs untreated control. 
b = Compound administered at 10 µM concentrations. DMSO 0.1% was used as a normalisation control. 
 
 Table 14 Summary of structure and biological activity for Series 4 
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Figure 27 the effects of all the chalcone derivatives on HUVEC viability.  
HUVECs were grown in 96 well plates at 5000 cell per well and left overnight. The media was changed and relevant concentrations of each compound was added, the cells were allowed to incubate for 72 hours. Following 
this 2mg/ml of MTT reagent was added and incubated for 4 hours. All media contents were removed and 100µl of DMSO was added. Plates were rocked and then the absorbance was recorded at 560nm.  
Dihydroxychalcone derivatives AH9 and AH12 were able to display similar effects to the parent compound AH1. Three and four positioned halogenated dihydroxchalcones (AH2, AH3, AH4 and AH5) did not exhibit as potent 
activity against HUVEC proliferation than AH1 and AH9 (the two 2-positioned dihydroxychalcone derivatives). Any repositioning or changes to the A ring did not improve the activity of the parent compound (AH15, AH16, 
AH17 and AH17a). The part derivative compounds (AHXRS1, AHXRS3 and AHXRS4) helped to confirm that the 2’5’-dihydroxy moiety is important to the compounds potent activity but only in conjunction with the 2-chlorine 
B ring. Also the part derivatives demonstrated how the 2 positioned B ring was more important to the overall activity than the 2’5’-dihydroxy A ring. Methoxylatedchalcone derivatives were able to exhibit potent activity at 
10 µM suggesting that the hydrogen donating ability of the hydroxyl groups were not integral to the activity observed. Values are means ± SEM of 4 independent experiments. Data expressed as a % vs untreated control. 
Compound administered at 10 µM concentrations. DMSO 0.1% was used as a normalisation control. 
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4.3 Further investigation of AH21 and AH21b (Series 6) 
 
Initial studies identified that hydroxyl groups acting as hydrogen donors on the A ring 
were not essential to the activity observed. To further explore, a mini SAR study was 
carried out on AH21b and AH21c. This was to see if re positioning certain substituent 
groups could alter the activity  
Firstly changing the positioning of the methoxy groups on the A ring from 2’5’ to 2’4’ 
(see Figure 28) were looked at to form AH22 and AH22a.  
 
 
 
 
 
 
 
 
Bertl et al (2004) study, as mentioned earlier, looked at a similar analogue – 3-bromo-
2’4’-dimethoxy derivative and exhibited anti endothelial activity and sub micromolar 
concentrations (Bertl et al., 2004). Therefore 3-bromo-2’4’-dimethoxychalcone (termed 
AH22s2 for this study) and 3-chloro-2’, 4’-dimethoxychalcone (AH22a) were 
synthesised and tested. AH22s2 refers to the second compound found in Bertl et al (2004) 
study that is related AH22 and its structure, hence s2 for 2nd standard compound.  
Cl O OMe
OMe
OMe
OMeBr O
OMe
OMe
Cl O
OMe
OMeBr O
AH21 AH22 
AH21b AH22a 
Figure 28 Synthesisng analogues of AH21 and AH21b to form 2'4'-dimethoxy derivatives AH22 and AH22a.  
This was carried out by using 2’4’-dimethoxyacetophenone for the starting material instead of 2’5’-
dimethoxyacetophenone.  
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What we found was that specific orientations were key to the activity observed. The 
substituents on one ring were important only in conjunction with specific orientation on 
the other ring. Having the 2-2’, 5’ orientation showed strong activity, but moving the 
methoxy group from 5’ to the -4’ position reduced the activity for both chloro and bromo 
derivatives (AH22 and AH22a). However keeping the A ring with the 2’4’-dimethoxy 
positioning but moving the halogen on the B ring from 2 to 3 position showed an increase 
in activity similar to the 2-2’,5’ orientation. This was interesting as it appeared to show 
that stereochemistry between the compounds was pivotal in exhibiting anti-endothelial 
activity at 10 µM.  
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Compound Structure 
Reduction in HUVEC 
viability a,b ± SEM 
AH21 
 
86.03 ± 3.26 
AH21b 
 
84.72 ± 4.56 
AH22 
 
38.89 ± 8.49 
AH22a 
 
66.45 ± 9.81 
AH22b 
 
89.08 ± 1.84 
AH22s2 
 
88.01 ± 1.93 
a = Values are means ± SEM of four independent experiments. Data expressed as a % vs untreated control. 
b = Compound administered at 10 µM concentrations. DMSO 0.1% was used as a normalisation control. 
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Cl O
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Cl
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O
 Table 15 Summary of structure and biological activity for Series 6 
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To further investigate potency, Ec50 determinations of the chosen lead candidates (AH1 
and AH9) along with Sorafenib were gathered using HillSlope’s nonlinear regression 
(table 16 and figure 29). It was interesting to see that for anti-proliferative activity against 
HUVECs across 72 hours, AH1 and AH9 exhibited superior activity than that of 
Sorafenib.  
Table 16 LD50 values of AH1 AH9 and Sorafenib, determined using HillSlope's nonlinear regression. 
 
 
 
 
 
 
Compound  LD50 (µM) 
AH1 4.14  
AH9 3.98   
Sorafenib 7.93   
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Figure 29 LD50 plots of AH1 AH9 and Sorafenib showing their anti-proliferative activity against HUVECs after 72 hour exposure. 
Values represented the averages of three independent experiments. Non-linear regression analyses were performed to obtain the LD50 values. 
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4.4 Conclusion:  
 
The structure activity relationships between all the compounds showed that a combination 
of electronegativity, stereochemistry and specific functional groups were vital to the 
potency of the activity observed. From series 1 it was evident that only specific substituent 
(EWGs) were favourable over ERG based substituent in that 2 position for exhibiting 
anti-proliferative activity. For series 2 it was clear that 2’5’-dihydroxy moiety specifically 
was key to the activity of AH1. Looking at series 3 it was interesting to find that the 2-
chlorophenyl on the B ring contributed more to the overall activity of AH1 than the 2’5’-
dihydroxy moiety on the A ring. Testing the 3 and 4 positioned chloro and bromo 
derivatives in series 4, helped to show that the position of the halogen at the 2 ring was 
integral to the anti-proliferative activity.  
Finally assessing the methoxy derivatives in series 5 suggested that the hydrogen donating 
ability of the hydroxyl groups were not essential in exhibiting anti-endothelial activity 
and that methoxy group substituents, which only possess hydrogen accepting capabilities, 
exhibited potent reduction in HUVEC viability at 10 µM. The parent compound AH1 
displayed the strongest anti-endothelial activity amongst all the tested compounds.  
Looking at all the series as a whole, the data suggested that the particular positioning of 
the chloro and hydroxyl groups on AH1 were pivotal and any manipulation whether 
substitution or re positioning (conducted in this study) did not cause any increase in 
activity. Out of the novel synthesised hydroxyl analogues, AH9 and AH12 displayed the 
best anti-proliferative activity towards HUVECs.  
Series 5 brought about a few interesting methoxy analogues (AH21, AH21b, AH22b, 
AH22s2) showing promising activity. But to remain within the initial aims, the hydroxyl 
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analogues were focused on. This was because the Series 2, 3 and 4 were focused on the 
hydroxyl element of AH1 and Series 5 was designed to just assess the hydrogen accepting 
ability of the A ring and not yield new methoxy compounds. Although these compounds 
could be investigated further.  
AH12 contains a nitro group that can be metabolically reduced to an aromatic amine 
which can lead to systemic toxicity (Benigni and Passerini, 2002; Skipper et al., 2010). 
Therefore, due to AH9’s better drug likeness over AH12, AH9 along with AH1 were put 
forward as the lead chalcone candidates on which to further test from to better understand 
their effects on endothelial cells. 
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Chapter 5: Anti-migratory analysis of 
lead candidates AH1 and AH9 
against HUVECs 
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5.1 Introduction: 
 
Reducing tumour induced angiogenesis as a means to regress tumour growth brought 
about the concept of producing synthetic antiangiogenic compounds (Kerbel and 
Folkman, 2002; Cook and Figg, 2010). The antiangiogenic activity of synthetic analogues 
has been assessed using both in vitro and in vivo models (Nam et al., 2003; Mojzis et al., 
2008; Lee et al., 2012). Although in vivo assays may offer more clinically relevant 
information, they are expensive and time consuming. Additionally, they are difficult to 
maintain due to specialist training and equipment, as opposed to in vitro assays (Auerbach 
et al., 2003). To add, these in vitro methods are well established as angiogenic functional 
assays with the majority of studies using HUVECs as the cell line of choice (Donovan et 
al., 2001; Nam et al., 2003; Goodwin, 2007; Varinska et al., 2012; Zhong et al., 2012). 
As the in vitro experiments are modelled on the vasculature, primary endothelial cells are 
suitable to use and can mimic in vivo angiogenic processes under the right conditions. To 
grow tubule networks in vitro, support matrices are needed to allow the endothelial cells 
to sprout. The most common extracellular matrix now used is Matrigel, derived from 
murine tumours (Kleinman and Martin, 2005). Therein, in vitro angiogenesis assays work 
on the basis that endothelial cells can grow and form tubule-like structures when 
supported by a culture matrix, mimicking the processes observed in vivo (Donovan et al., 
2001).  
 
 
 
AH1 AH9 
OH
OHBr OOH
OH
Cl O
Figure 30 Chemical structures of lead chalcones AH1 and AH9. 
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Endothelial proliferation, migration and differentiation are three distinct areas studied in 
antiangiogenic models (as discussed in Chapter 1). Each stage is related to a specific 
phase in the angiogenesis process and studying these in isolated assays can provide insight 
as to the where the lead compounds exert their activity. As proliferation studies were 
conducted via the MTT assay in chapter 4, this chapter centres around the effects of the 
lead candidates on endothelial migration. 
Cell motility is a key target for designing anti-cancer therapies, as cell migration is 
essential for both tumour invasion and tumour induced angiogenesis (Palmer et al., 2011; 
Wells et al., 2013). As a result, multiple assays have been utilised in vitro to analyse the 
anti-migratory effects of an agent such as the wound healing, transwell and under-agarose 
assays (Dredge et al., 2005; Goodwin, 2007). The transwell and under-agarose assays 
require specific well plates and complex chambers to form the migratory model, which 
can create difficulty in acquiring consistent reliable results, due to the specialised 
apparatuses and methodology needed (Staton et al., 2004).  
The wound healing (also known as scratch) assay offers simplistic methodology, robust 
results and is widely used to mimic in vivo models (Liang, Park and Guan, 2007). The 
wound healing assay works by creating a synthetic wound across a endothelial cell 
monolayer. The width or area of the wound in measured thereafter (this equals time zero), 
then subsequent migration is characterised over a period of time.  
A study by Dredge and colleagues (2002) used the scratch assay to identify anti-migratory 
activity of immunomodulatory thalidomide analogues. Njardarson and colleagues (2004) 
identified a potent tumour cell migration inhibitor, an analogue of a natural product 
migrastatin, as a result of using the scratch assay (Dredge et al., 2002; Njardarson et al., 
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2004). As a result, it was chosen as the most suitable assay to determine the migratory 
response of endothelial cells to the lead candidates AH1 and AH9 (Auerbach et al., 2003).  
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5.2 Results and discussion:  
5.2.1 Endothelial cell migration – wound healing assay  
 
The wound healing assay was used to determine the migratory response of endothelial 
cells to the lead candidates. Cells were cultured in multiwell plates and then scratched 
down the middle by a pipette tip (see figure 31). The migration that occured was measured 
by assessing the width of the wound between monolayers over time. In this case 
preliminary experiments indicated that wound closure (HUVECs in 6 well plates with 
EM200 media (supplemented with LSGS)) occurred around 8 hours. Therefore we 
elected to use 8 hours as the end point with one interval in between for comparison (4hr). 
Images were taken at these regular time points (0hr, 4hr and 8hr) to observe the 
development of any migration seen. The average distance between the wound was 
calculated over the time points as a measure of migration.  Images were taken of 3 
randomly selected fields at 100x magnification.  
 
 
 
 
 
 
0hr 
8hr 
4hr 
Width of the wound 
Figure 31 A abstract diagrammatic representation of wound closure in a wound healing assay over 8 hours.  
The diagram illustrates the width of the wound closing over time, therefore this assay can be used to 
measure endothelial cell migration in the presence or absence of stimulating factors or synthesised 
compounds.  
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5.2.2 Preliminary study to identify optimal concentration for the wound healing 
assay 
Preliminary experiments were conducted at 10 µM, 3 µM and 1 µM for both AH1 and 
AH9. At 10 µM cell death was seen by 8 hours, this was indicating the concentration was 
too toxic for the cells. Figure 32 illustrates the comparison in the change of morphology 
in HUVECs across the time points with different concentrations, with 10 µM 
concentration showing aforementioned cell death by 8 hours. From these images it is clear 
that the viability of the cells were healthier in the 3 µM and 1 µM concentrations 
experiments. 
Having identified that 10 µM concentration was too high for this particular assay, the two 
lower non-toxic concentrations (3 µM and 1 µM) were taken forward. Sorafenib (3 µM) 
was also used as a positive control.  
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0hr 4hr 8hr 
10 µM 
3 µM 
1 µM 
Figure 32 The effects of AH1 on HUVEC migration:  
The images iterate how at 10 µM AH1 showed apoptotic cell death by 8 hours. This suggested the concentration was too high as a dose to use in this scratch assay. To further support this the 
images taken at 3 µM and 1 µM showed healthy HUVECs by 8 hours. Therefore, 3 µM and 1 µM were taken forward as the concentrations to use in this assay.  
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5.2.3 AH1  
Results for AH1 showed that at 3 µM, the parent compound displayed similar anti-
migratory activity to that of Sorafenib when compared to time 0hr control (at 4 hours, 
AH1 vs Sorafenib = (28.8%) vs (34.5%), respectively, p = 1.0). Table 17 demonstrates 
the width of wounds gathered for each experiment and shows a clear difference in width 
between the untreated control, AH1 3 µM and Sorafenib 3 µM. At 8 hours also, no 
significant difference was seen in migration between AH1 and Sorafenib at 3 µM (AH1 
vs Sorafenib = (47%) vs (52.7%), respectively, p = 1.0). Figure 33 illustrates the images 
taken during the scratch assay experiment.  
When compared to the untreated control at both 4 and 8 hours, AH1 and Sorafenib (at 3 
µM) did not show any significant difference in terms of % migration (see Table 18); (at 
4 hours, AH1 vs Untreated control = (28.8%) vs (44.9%), respectively, p = 0.77); (at 4 
hours, Sorafenib vs Untreated control = (34.52%) vs (44.9%), respectively, p = 1.0); (at 
8 hours, AH1 vs Untreated control = (47.2%) vs (75.2%), respectively, p = 0.19); (at 8 
hours, Sorafenib vs Untreated control = (52.68%) vs (75.2%), respectively, p = 0.41). 
Figure 34 illustrates the change in migration observed for the AH1 experiment.  
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Untreated control AH1 3µM Sorafenib 3µM 
8hr 
Ohr 
4hr 
  
Figure 33 Select photos of from the unstimulated scratch assay.  
From the wells of untreated control, AH1 3 µM and Sorafenib 3 µM. The images show the wound closure as expected in the untreated control. Anti-migratory effects were seen with 
AH1 and Sorafenib at 3 µM.  
 
133 
Table 17 Showing the average width of wounds (µm) for each gathered from three independent experiments 
(untreated control, AH1 3µM, 1µM and Sorafenib 3µM) with time points ± SEM. * = p < 0.05 vs time matched 
untreated control (statistical analysis carried out by one way –ANOVA followed by Tukey-Kramer post hoc t test for 
multiple comparisons).  
 
 
  
Table 18 showing the % migration of the untreated control, AH1 (3µM) and Sorafenib (3µM) after 8hrs of 
incubation.  
Values are % migrations compared to time 0 hr. 
 
 
Time Untreated control AH1 1 µM AH1 3 µM Sorafenib 3 µM 
Ohr 523.93 ± 30.01 575.47 ± 30.25 511.57 ± 28.24 611.64 ± 39.55 
4hr 286.28 ± 25.22 343.53 ± 28.63 363.21 ± 13.01 410.27 ± 16.75 
8hr 157.55 ± 25.99 116.52 ± 58.83 269.75 ± 37.24 266.86 ± 18.73 
 % migration across 8 hours 
Untreated control 69.81 
AH1 47.23 
Sorafenib 55.77 
134 
0
100
200
300
400
500
600
700
0hr 4hr 8hr
W
id
th
 o
f w
ou
nd
  (
µm
)
Time (hr)
Untreated control
AH1 3 µM
Sorafenib 3 µM
AH1 1 µM
Figure 34 Figure Effects of AH1 on HUVEC migration across 8 hours. 
HUVECs (grown in 6 well plates) were scratched down the middle by a p1000 tip and briefly washed with cold PBS. Media was added with the relevant compound and control concentrations. Images were taken at periodic 
intervals. The data present are mean values gathered from three independent experiments ± SEM. Responses were compared using one way-ANOVA with Tukey-Kramer multiple comparisons post hoc t test. The inhibitory 
effects caused by AH1 (3 µM) were not statistically significantly different to that caused by Sorafenib (3 µM). * = P<0.05 vs. untreated control.  
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5.2.4 AH9  
Interestingly, results for AH9 at 3 µM demonstrated a significant increase in anti-
migratory activity at both 4 and 8 hours when compared to Sorafenib, with AH9 appearing 
to show regression in HUVEC migration (when both were compared to their time 0hr 
controls); (at 4 hours, AH9 vs Sorafenib = (-4.9%) vs (34.5%), respectively, p < 0.03); 
(at 8 hours, AH9 vs Sorafenib = (16.2%) vs  (52.7%), respectively, p < 0.05). Table 19 
and figure 35, demonstrates the width of wounds for each experiment clearing presenting 
a difference between wounds size for AH9 3 µM and Sorafenib 3 µM compared to the 
untreated control.  
Unlike AH1, AH9 did showed significant anti-migratory activity when compared to the 
Untreated control at both 4 and 8 hours (see Table 20); (at 4 hours, AH9 vs Untreated 
control = (-4.9%) vs (44.9%), respectively, p < 0.004); (at 8 hours, AH9 vs Untreated 
control = (16.2%) vs (75.2%), respectively, p < 0.0007).  
AH9 at 3 µM also exhibited a marked increase in the inhibition of HUVEC migration 
compared to AH1 at both 4 and 8 hours (see Figure 37). 
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Table 19 showing the average width of wounds (µm) for each gathered from three independent experiments 
(untreated control, AH9 3 µM, 1 µM and Sorafenib 3 µM) with time points ± SEM; * = p < 0.05 vs time matched 
untreated control (statistical analysis carried out by one way –ANOVA followed by Tukey-Kramer post hoc t test for 
multiple comparisons). 
 
 
Table 20 showing the % migration of the untreated control, AH9 (3µM) and Sorafenib (3µM) after 8hrs of 
incubation. 
Values are % migrations compared to time 0 hr.  
 
 
 
 
 
 
 
 
 
Time Untreated control AH9 1 µM AH9 3 µM Sorafenib 3 µM 
Ohr 537.16 ± 20.25 576.25 ± 16.64 505.13 ± 21.77 569.35 ± 43.91 
4hr 297.47 ± 30.17 369.50 ± 50.63 526.74 ± 17.86* 356.47 ± 3.68 
8hr 107.21 ± 61.59 114.02 ± 59.64 417.16 ± 53.02* 287.36 ± 29.13 
 % migration across 8 hours 
Untreated control 80.04 
AH9 17.41 
Sorafenib 49.53 
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Figure 35 Effects of AH9 on HUVEC migration across 8hrs. 
HUVECs (grown in 6 well plates) were scratched down the middle by a p1000 tip and briefly washed with cold PBS. Media was added with the relevant compound and control concentrations. Images were taken at 
periodic intervals. The data present are mean values gathered from three independent experiments ± SEM. Responses were compared using one way-ANOVA with Tukey-Kramer multiple comparisons post hoc t 
test. The anti-migratory effects caused by AH9 were statistically significantly different to that of the untreated control. * = P<0.05 vs. time matched (8 hours) untreated control. 
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5.3 Conclusion 
 
Overall, AH9 across 8hrs was able to limit HUVEC migration to 16% (p < 0.0007) 
compared to the untreated control of 80% (See table 18 and 19). Sorafenib at 3 µM was 
able to limit migration to 52.7% (p > 0.4). 
Figure 37 illustrates the difference in activity between AH1 and AH9. AH1 was able to 
limit migration to 47% whereas AH9 could limit it to 16% at the 8 hour time period.  
As both compounds are analogues of each other differing only at the ortho position on 
the B ring (figure 36), it raises the question as to why the bromine derivative (AH9) 
demonstrated significantly more potent anti-migratory activity compared to its chlorine 
counterpart (AH1).  
 
 
 
 
 
Taken together with the anti-proliferative data in chapter 4, these observations suggest 
that AH9 inhibits HUVEC proliferation and significantly limits HUVEC migration, two 
hallmark characteristics of an agent capable of being developed as an angiogenesis 
inhibitor (Staton et al., 2004).
AH1 AH9 
OH
OHBr OOH
OH
Cl O
Figure 36 Chemical structures of AH1 and AH9. 
 Colour boxes highlight the different halophenyl rings and how the change from chlorine to 
bromine at the ortho position causes a significant increase in the anti-migratory activity 
observed against HUVECs after 8 hour exposure at 3 µM. 
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Figure 37 Effects of AH1, AH9 and Sorafenib (3 µM) on HUVEC migration, over 8 hours. 
The data present are mean values gathered from three independent experiments ± SEM 
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Chapter 6: Pharmacological 
evaluation of AH9 
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6.1 Introduction: 
 
After establishing that AH9 displayed promising in vitro antiangiogenic activity, the next 
phase of the work was to understand AH9’s mechanism of action for the observed anti-
migratory activity. Molecular mechanism of actions (MMOA) of lead compounds are an 
essential criteria in drug development (Schenone et al., 2013). By knowing the MMOA, 
derivatives can be formulated to build upon the existing efficacy of original drugs 
(Swinney and Anthony, 2011). In clinical drug detection, MMOA can help to identify 
drug metabolism and excretion in response to certain proteins the drug targets. Finally 
having information like MMOA can enable researchers to explore other possible 
applications and uses for that particular drug (Tari et al., 2012).  
Pharmacological profiling is central for lead candidate’s progression to pre-clinical 
stages. Understanding how a drug is causing its desired effect can be analysed in 
numerous ways. Effects on protein/receptor expression is one the most widely used tool 
for mechanistic evaluation (Forstner, Leder and Mayr, 2007).  Assessing the up-
regulation or inhibition of a protein and subsequently their signalling pathways involves 
techniques such as gel electrophoresis, western blot analysis and immunohistochemistry. 
Within this, computer modulation and digital molecular docking software’s have been 
employed to predict and visualise drug-protein interactions (Gschwend, Good and Kuntz, 
1996; Kitchen et al., 2004; Vilar, Cozza and Moro, 2008). 
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ERK (extracellular signal-regulated kinase) is a key signalling mediator for cell migration 
in endothelial cells (Huang, Jacobson and Schaller, 2004; Chen et al., 2009; Srinivasan 
et al., 2009). As discussed in chapter 1, VEGF mediates its angiogenic property by 
activating its receptor and initiating downstream signalling pathway including ERK ½. 
Thereon, AH9’s effect on VEGF-induced ERK 1/2 activation were initially assessed to 
see if the anti-migratory activity identified in Chapter 5 is linked to the inhibition of ERK 
1/2 expression and/or downregulation of ERK 1/2 phosphorylation. Expression of 
VEGFR-2 in HUVECs in the presence of AH9 were also preliminarily investigated 
afterwards. 
Several studies use multiple concentrations when assessing the effects of an agent on 
protein expression or phosphorylation (Lee et al., 2012; Varinska et al., 2012; Xu et al., 
2017). Lee and colleagues used 10 µM, 5 µM and 1 µM for their work on assessing 
inhibitory effects of diphenylpropenones on VEGFR-2 phosphorylation when stimulated 
with VEGF (Lee et al., 2012). A study conducted by Varinska and colleagues (2012) used 
100 µM and 10 µM when evaluating the effects of Q797 (4-hydroxychalcone) on ERK 
and Akt phosphorylation stimulated by bFGF and VEGF separately (Varinska et al., 
2012). Xu and colleagues (2007) used a three concentration screen of 10 µM 5 µM and 1 
µM when measuring the effects of Cryptotanshinone on ERK phosphorylation (Xu et al., 
2017). When considering all of these studies the following concentrations were used for 
this study, 100 µM, 30 µM and 10 µM. These were selected to match up to previous 
studies carried out.   
 
 
143 
6.2 Results and Discussion: 
6.2.1 Experimental design for analysis of protein expression  
HUVECs were seeded in serum free media and pre-treated with AH9 at indicated 
concentrations for 1 hour. Cells were stimulated with or without 30 ng/ml of VEGF 15 
minutes prior to cell lysate collection. Specific antibodies were used to detect for 
phosphorylated-ERK, total-ERK, VEGFR-2 and β-actin.  
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6.2.2 AH9’s effects on Erk 1/2 expression and phosphorylation  
 
These studies identified that AH9 significantly inhibited VEGF-induced phosphorylation 
of ERK ½ (figure 39), (p < 0.0001).Therefore this could be the reason behind the 
compound’s potent anti-migratory activity towards HUVECs (see chapter 5). Sorafenib, 
as expected significantly reduced ERK phosphorylation to the point where densitometry 
analysis could not pick up a signal (see figure 38) when compared to the rest of the bands 
on the membrane (Murphy et al., 2006). Out of the two ERK isoforms (p44 and p42) 
identified in Figure 38, VEGF was shown to stimulated p42 ERK phosphorylation. 
 
 
  
 
VEGF - + + + + + 
AH9 - - 100  µM 30  µM 10  µM - 
Sorafenib - - - - - 30  µM 
MW (kDa) 
42 
42 
44 
45 
p-ERK 
Total-ERK 
Β-actin 
Figure 38 membrane captures of AH9's effect on ERK phosphorylation.  
HUVECs were stimulated with or without VEGF, the images presented are the exposures as a result. ECL, made in situ 
was used for chemiluminescence with HRP conjugated secondary antibodies.  
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Figure 39 effects of AH9 on ERK phosphorylation. 
HUVECs were stimulated with or without VEGF with relevant concentrations of AH9. Cell lysates were gathered and heatblocked. Cell lysates were ran on a SDS-gel page electrophoresis followed by 
western blot onto a nitrocellulose membrane. Selected primary antibodies were used to probe for desired proteins. HRP-conjugated secondary antibodies and ECL were used to visualise the protein 
bands via chemiluminescence. 
AH9 was able to significantly inhibit at all three concentrations 100 µM (* = p < 0.003), 30 µM (** = p < 0.0002) and 10 µM (*** = p < 0.0001) compared to the VEGF control. Sorafenib at 30 µM showed 
complete inhibition of ERK ½ phosphorylation (* = p < 0.0001) with no observable signal when compared to the rest of the bands on the nitrocellulose membrane. Unexpectedly less inhibition was seen 
at the higher concentrations (100 µM and 30 µM) when compared to 10 µM results. This could have been due to poor solubility seen when AH9 was administered to serum free media. Precipitation was 
seen especially at 100 µM. Also these concentration may have been toxic towards the cells as inhibitory studies on protein expression are usually found at lower concentrations for example 10 µM. 
Membrane captures were quantified using densitometry, levels of proteins were quantified and normalised using B actin as an internal control. Ratio of phosphorylated ERK vs total ERK were expressed 
as means of three independent experiments ± SEM. Responses were compared using one way-ANOVA with Tukey-Kramer multiple comparisons post hoc t test. 
** 
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6.2.3 AH9’s effects on VEGFR-2 expression stimulated with VEGF 
 
Assessing the interaction with VEGFR-2. AH9 was able to inhibit the expression of 
VEGFR-2 in a dose dependent manner (100µM, 30µM). See figure 40 below and figure 
41. 
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Figure 40 membrane captures of AH9's effect on VEGFR-2 expression. 
HUVECs were stimulated with or without VEGF, the images presented are the exposures as a result. 
ECL, made in situ was used for chemiluminescence with HRP conjugated secondary antibodies 
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Figure 41 effects of AH9 on VEGFR-2 expression.  
HUVECs were stimulated with or without VEGF with relevant concentrations of AH9. Cell lysates were gathered and heatblocked. Cell lysates were ran on a SDS-gel page electrophoresis followed by 
western blot onto a nitrocellulose membrane. Selected primary antibodies were used to probe for desired proteins. HRP-conjugated secondary antibodies and ECL were used to visualise the protein 
bands via chemiluminescence. AH9 was able to reduce the expression of VEGFR-2 at all three chosen concentrations. Sorafenib also showed reduced in VEGFR-2 expression. Membrane captures were 
quantified using densitometry, levels of proteins were quantified and normalised using β-actin as an internal control. Ratio of VEGFR-2 vs β-actin were expressed as means of two independent 
experiments ± SEM. 
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6.2.4 Overall discussion on mechanistic studies 
These results link back to Varinska et al and their work on Q797 (4-hydroxychalcone) 
(Varinska et al., 2012). They concluded that at 100 µM Q797 was able to inhibit VEGF-
induced ERK-phosphorylation. Here we report a 10-fold lower and much safer 
concentration (10 µM) to inhibit ERK phosphorylation (p < 0.0001). Further studies will 
assess the lowest concentration achievable to inhibit ERK phosphorylation.  
To note, at the higher concentrations (100 µM and 30 µM) inhibition of ERK 
phosphorylation was significantly less 10 µM. looking back at the experimental design, 
AH9 at the concentrated doses showed poor solubility in serum free media. In 5% serum 
media used for the anti-proliferative work in Chapter 4 AH9 was well tolerated up to 
concentrations of 30 µM. With 10 µM being further diluted before being administered 
into the well, we believe its solubility was more favoured and as a result it was able to 
exhibit the inhibitory activity seen in Figure 39. Intracellular over saturation of AH9 could 
also be the reason behind the reduced ERK inhibition when compared to a more 
commonly seen dose (10 µM) in ligand binding studies of lead compounds. Also the 
preliminary studies on the effect of AH9 on VEGFR-2 expression showed a decreased in 
receptor expression. This would correlate to a reduction in receptor activation and as a 
result reduce the phosphorylation of the interactive downstream signalling mediators. 
Therefore the reduction in ERK phosphorylation by AH9 could be the result of reduced 
VEGFR expression. Whether this is linked to a reduction in VEGFR phosphorylation 
requires further investigation. However as this stage we cannot identify with kinase 
(MAP3K, MAP2K and MAPK) AH9 is affecting in particular and would need further 
probing.  To add, we cannot rule out that AH9 could be increasing the activity of 
phosphatases that could cleave off phosphate groups causing the decrease 
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phosphorylation seen. This would also need investigating via phosphatase colorimetric 
assays for example.   
To summarise, these results provide an introductory understanding about the molecular 
mechanism of action for AH9; in relation to its anti-migratory effect against HUVECs. 
ERK function as highlighted in Chapter 1.2.3. is an fundamental signalling molecule for 
endothelial proliferation and migration. These results show AH9 as a potent ERK 
phosphorylation inhibitor. The findings also relate to the significant inhibition of ERK 
phosphorylation by Sorafenib conducted in this study (p < 0.0001). As highlighted in 
Chapter 1.3 these outcomes support the literature studies on Sorafenib’s effects on ERK 
expression. But they also further demonstrates how AH9, a simple molecular compound, 
exhibited similar activities to that of a licensed FDA approved drug for antiangiogenic 
therapy, on reducing ERK phosphorylation in vitro.  
Further work is needed to investigate the VEGFR-2 phosphorylation, in response to 
exposure to AH9 to gauge a better understanding of the molecular mechanism of action. 
Especially if AH9 is affecting other signalling pathways that stimulate ERK e.g. FGFR 
pathway or exhibiting deregulation effects on ERK phosphorylation directly. As 
mentioned in Chapter 1.2.4, FGFR and ANGPT-2 pathways are important in the 
angiogenesis cascade especially after the onset of resistance to VEGFR targeted therapies. 
Therefore AH9’s effects on these pathways should be further explored. Figure 42, 
illustrates a preliminary mechanism of action for AH9.  
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Figure 42 preliminary mechanism of action of AH9. 
Studies have confirmed the significant inhibition of ERK phosphorylation that could be the 
cause of the anti-migratory activity seen. The question mark relates to further testing needed 
to support if AH9 is inhibiting VEGFR-2 phosphorylation. 
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Chapter 7: Conclusion and Future 
Directions  
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7.1 Conclusion: 
The main aim of this project was to identify derivatives with superior anti-angiogenic 
properties to AH1 and to evaluate a preliminary mechanism of action. In order to achieve 
this, five series of chalcones were designed and synthesised, all addressing a key part of 
the parent compound AH1. Lead compounds were identified first through anti-
proliferative screening. Thereafter, anti-migratory analysis of the lead candidate AH9 (2-
bromo-2’5’-dihydroxychalcone) and parent compound AH1 (2-chloro-2’5’-
dihydroxychalcone) compounds were evaluated. In addition, the preliminary molecular 
mechanism of action of AH9 has also been investigated. 
Our data suggests that both AH1 and AH9 exhibit similar anti-proliferative activity at 
micromolar concentrations against HUVECs. But more importantly, AH9 exhibited 
significantly more potent anti-migratory effects against HUVECs than AH1 and 
Sorafenib. Our studies have shown that AH9 has strong inhibitory effects on endothelial 
cell proliferation and significant potent effects on endothelial migration.  These are two 
hallmark characteristics of an agent capable of being developed as an angiogenesis 
inhibitor. Mechanistic evaluation identified that AH9 could be exhibiting its anti-
proliferative and anti-migratory activity via inhibiting VEGF-induced phosphorylation of 
ERK. Therefore, the study has successfully identified an agent superior to AH1 and 
demonstrated a preliminary mechanism of action, meeting the original aims of the project. 
This work also demonstrates how chalcones are suitable parent compounds on which to 
identified lead compounds of interest like AH9 and presents a strong case for further lead 
optimisation cycles. 
As an inhibitor of endothelial cell migration, AH9 stands as a promising agent for anti-
angiogenic therapy and warrants further investigation.  
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7.2 Study limitations 
For the organic synthesis, there were limitations that restricted the range of compounds 
that could have been made. The availability of the NMR was a significant issue which 
limited the progression of the syntheses. Intermediates or co running spots on the TLCs 
for the hydroxychalcones, caused difficulty in separation via column chromatography. 
This resulted in the lower yields seen for some compounds.  
The biggest limitations for this study was the amount of time taking to optimise 
experimental conditions for the syntheses and to gain access to core materials (thionyl 
chloride and the HUVECs). It took an extra 8 months than scheduled to synthesise all the 
designed compounds and, in this time, the HUVECs were still not obtained. As a result, 
the window to screen all the compounds was significantly reduced and limited the scale 
of assays that could have been conducted. 
In regard to the wound healing assay, automated or commercial computer software like 
the Wimasis Image Analysis or Ibidi Wound Healing ACAS Image Analysis are available 
to analyse the images. Analysis is done far quicker than the manual method that was used 
in this study (1-2 days compared to 1-2 weeks per experiment). This would have allowed 
time to take more photos for a better, more representative analysis of the wound migration 
over time. However, the manually-obtained images were sufficient to demonstrate the 
effects of synthesised compounds on endothelial migration.  
To add, in vivo migratory models would have strengthened the defence for the anti-
migratory activity identified. However as highlighted earlier the shortened window to 
screen all the compounds also meant there was a reduced time to assess the functional 
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capabilities of lead candidates. This was also the reason why other in vitro assays 
assessing endothelial differentiation were not able to be completed in this study.  
7.3 Future directions 
AH9 was generated and analysed using hit-to-lead optimisations, in vitro and mechanistic 
studies. However further lead optimisations and mechanistic studies are still needed. AH9 
exhibited potent activity in in vitro cell assays, but the enone moiety of AH9 may be 
subjected to significant metabolic breakdown by the liver. On top, AH9 is quite lipophilic 
(c log p) and thus possesses poor water solubility, therefore lead optimisation cycles for 
improving pharmacokinectic parameters would be useful to improve the overall drug 
likeness of AH9. Examples such as converting the chalcone structure into heterocyclic 
compounds like pyridine and pyrimidines could be carried out. These compounds can be 
formed as water soluble salts in an attempt to improve water solubility.  
The angiogenic process encompasses several key receptors and signalling mediators. Two 
of out the three hallmarks (proliferation and migration) have been investigated 
preliminarily in this study. The effects of AH9 on endothelial cell differentiation (third 
hallmark) via in vitro assays like the tube formation assay would help to solidify or better 
understand how AH9 exerts in anti-angiogenic effects.  
Assessing the effects of AH9 on VEGFR-2 phosphorylation, as discussed in Chapter 
6.2.4, is important to gauge a more complete view on the mechanism of action for AH9.  
Stimulated studies using VEGF and other angiogenic ligands e.g. ANG-1 in more 
advance in vitro cell models is quite a key development from this study. Models like 3D 
cell culture and co culture would generate deeper insights into the anti angiogenic effects 
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of AH9 in more specific and representative conditions i.e. selecting specific tumours cells 
to grow with HUVECs to assess AH9’s interactions in a dual approach study.  
Synergestic or combinatorial studies (as mention in Chapter 1.3.3) are becoming a focal 
point in modern day pharmacology.  As complex diseases progress the efficacy of 
monotherapy is reducing and the need for polypharmacology increasing. Therefore, 
studies assessing AH9 with current licensed antiangiogenic drugs could be a strong 
progression, stemming from this study as a foundation.  
Synergestic interactions and improving the drug likeness of AH9 will be the main goals 
in future studies. 
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Chapter 8: Experimental 
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8.1 Experimental: 
8.2 General chemical procedures (Materials & Methods)  
8.2.1 Reagents   
Starting materials and reagents were used as received from Sigma-Aldrich Chemical 
Company (Dorset UK). General laboratory solvents were purchased from Fisher 
Scientific, Loughborough, UK. 
8.2.2 Equipment: 
Nuclear magnetic resonance spectroscopy (NMR) was used as the primary structure 
confirmation tool.  1H and 13C NMR spectra were recorded on a Bruker Avance super-
conducting AV400 NMR spectrometer at 30oC. Chemical shifts are reported in units 
relative to the TMS signal standard and coupling constants (J) are expressed as Hertz 
(Hz). 1H NMR peak information is provided in the following format: number of protons, 
multiplicity, coupling constant (where appropriate) and peak signal. Multiplicities are 
reported as: singlet (s), doublet (d), triplet (t), doublet of doublets (dd), doublet of doublet 
of doublets (ddd), doublet of triplets (dt), triplet of doublets (td), multiplet (m).  
High resolution mass spectrometry (HRMS) was carried out using a Thermo Scientific 
LTQ Orbritrap XL mass spectrometer at EPSRC UK National Mass Spectrometry 
Facility, Swansea University. Infra-red (IR) spectra were recorded on a Bruker Alpha 
ATR module (101873) spectrophotometer with bond absorptions reported as cm-1. 
Melting points (M.P) were carried using a Gallenkamp melting point apparatus in open 
glass capillary tubes and are uncorrected. Thin layer chromatography (TLC) was 
performed using Merck Aluminium Sheet – Silic Gel 60f254 coated plates. TLC plates 
were visualised using a Multiband UVGL-58 UV 254/366nm lamp. Staining of TLC 
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plates to visualise compounds were done using 2,4-diphenylhydrazine (DNP), 
phosphomolybdic acid (PMA) or iodine absorbed on sand. Silica gel (Fluka Silica 60; 
standard 25-70u or fine grade 2-45u) were used to perform flash column chromatography.  
Ultraviolet (UV) spectra were recorded on a Thermo Scientific Helios Gamma 110-240 
Volts UV-VIS spectrophotometer. HPLC was carried out on a Perkin Elmer 200 series 
chromatography system using a Perkin Elmer C18 (250 x 4.6mm) column using the 
following isocratic elution methods: 
Method 1: 70 % acetonitrile/ water (Flow rate = 1.5 mL/ min, λ = λ max of compound) 
Method 2: 90 % acetonitrile/ water (Flow rate = 1.5 mL/ min, λ = λ max of compound) 
All samples had purity of 95% or greater.  
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8.2.3.1 Experimental protocols: 
8.2.3.2 Chalcone synthesis method 1 (Nam et al, 2003) 
2’,5’-Dihydroxyacetophenone (1.00g 6.57mmol) and pyridinium p-toulene sulphonate 
(0.04g 0.159mmol) were dissolved in anhydrous dichloromethane and stirred for 30 
mintues at room temperature. A solution of 3,4-dihydro-2H-pyran (3.4 mL 37mmol) in 
dichloromethane (20 mL) was added and stirring continued for 4h. The solution was 
washed with water (2x30 mL) and the organic layer dried over anhydrous magnesium 
sulphate. Removal of the solvent under vacuo yielded crude 2’5’-bis(tetrahydropyran-2-
yloxy)acetophenone as a straw coloured oil. 
Barium hydroxide octahydrate (2.15g 6.57mmol) was added to a stirred solution of the 
appropiate benzaldehyde (6.57mmol) and crude 2’5’-bis(tetrahydro-pyran-2-
yloxy)acetophenone at room temperature. After 18h the reaction mixture was washed 
with water (2x30 mL) and the organic layer dried over anhydrous magnesium sulphate. 
Removal of the solvent in vacuo yielded crude (E)-1-[2,5-(bis(tetrahydropyran-2-yloxy)-
phenyl]-3-phenyl-2-propene-1-one as an orange solid. 
A solution of p-toulenesulphonic acid (0.44g 2.34mmol) and crude (E)-1-[2’5’-
(bis(tetrahydropyran-2-yloxy)-phenyl]-3-phenyl-2-propene-1-one in methanol (30 mL) 
was stirred at room temperature for 30mins. The reaction mixture was quenched with 
water (30 mL) and extracted with ethyl acetate (2x30 mL). The oragnic extracts were 
dried over anhydrous magnesium sulphate and the solvent removed under vacuum. The 
residue was purified by either flash column chromatography (hexane/ethyl acetate 8:2) or 
recrystalisation from ethanol.  
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(E)-3-(2-Bromophenyl)-1-(2,5-dihydroxyphenyl)-2-propene-1-one (AH9) 
Recrystalisation from ethanol. Red/orange crystals (35%). mp 177-179oC; TLC: Rf = 0.13 
(hexane/ethyl acetate 8:2); IR: (ATR)/cm-1  3354 (OH), 1641 (C=O); 1H NMR (ppm, 
DMSO-d6): 6.85 (1H, d, J = 9.4Hz, Ar), 7.04 (1H, dd, J = 9.4, 3.1Hz, Ar), 7.39 (1H, ddd, 
J = 7.8, 1.9Hz Ar), 7.48 (2H, m, Ar), 7.75 (1H, dd, J = 9.4, 1.4Hz, Ar), 7.91 (1H, J = 
15.6Hz, C=CH), 8.02 (1H, J = 15.6Hz, C=CH), 8.14 (1H, dd, J = 9.4, 1.4Hz Ar), 9.20 
(1H, s, OH), 11.50 (1H, s, OH); 13C NMR (DMSO-d6) 115.1, 118.3, 121.3, 124.5, 125.4, 
125.5, 128.8, 132.3, 133.3, 133.8, 141.1, 149.6, 154.2, 192.6; HMRS found [M+1]+ 
318.9969, C15H11O3Br [M+1]+ 318.9964;  Purity > 99% HPLC method 1 (Retention time 
4.114 min).  
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 (E)-1-(2,5-dihydroxyphenyl)-3-(2-methylphenyl)-2-propene-1-one. (AH10) 
Recrystalisation from ethanol. Bright red crystals (20%); mp 174-176oC; TLC: Rf = 
0.54 (hexane/ethyl acetate 7:3); IR: (ATR)/cm-1  3291 (OH), 1635 (C=O); 1H NMR 
(ppm, DMSO-d6): 2.44 (3H, s, CH3), 6.86 (1H, d, J = 9.1Hz, Ar), 7.03 (1H, dd, J = 9.1, 
3.6Hz, Ar), 7.20-7.38  (2H, m, Ar), 7.36 (1H, td, J = 5.5, 1.8Hz, Ar), 7.48 (1H, d, 
3.8Hz, Ar), 7.81 (1H, d, Ar) (1H, J = 14.5 Hz, C=CH), 7.94 (1H, d, J = 9.1Hz, Ar), 8.02 
(1H, d, Ar) (1H, J = 14.5 Hz, C=CH), 9.20 (1H, s, OH), 11.65 (1H, s, OH); 13C NMR 
(DMSO-d6) 115.0, 118.3, 121.1, 123.2, 124.3, 126.4, 127.0, 130.6, 130.9, 133.1, 138.2, 
141.2 ,149.5, 154.4, 193.0; HMRS found [M+1]+ 255.1018, C16H14O3 [M+1]+ 
255.1016; Purity > 98% HPLC method 1 (Retention time 3.57 min). 
 
 
 
 
 (E)-1-(2,5-dihydroxyphenyl)-3-(2-fluorophenyl)-2-propene-1-one. (AH11) 
Recrystalisation from ethanol. Dark brown crystals (26%); mp 192-194oC; TLC: Rf = 
0.45 (hexane/ethyl acetate 7:3); IR: (ATR)/cm-1 3346 (OH), 1643 (C=O); 1H NMR (ppm, 
OH
OHF O
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DMSO-d6): 6.85 (1H, d, J = 8.6Hz, Ar), 7.03 (1H, dd, J = 8.6, 2.9Hz, Ar), 7.27-7.35 (2H, 
m ,Ar), 7.40 (1H, d, J = 2.9Hz, Ar), 7.49-7.56 (1H, m, Ar), 7.83 (1H, J = 16 Hz, C=CH), 
7.93 (1H, J = 16 Hz, C=CH), 8.04 (1H, ddd, J = 8.6, 1.4Hz, Ar), 9.30 (1H, s, OH), 11.50 
(1H, s, OH); 13C NMR (DMSO-d6) 114.9, 116.0, 116.2, 118.4, 121.3, 122.1, 122.2, 124.4, 
124.9, 124.9, 125.0, 129.6, 132.8, 132.9, 135.4, 135.4, 149.6, 154.2, 192.7; HMRS found 
[M+1]+ 259.0768, C15H11O3F [M+1]+ 259.0765; Purity > 98% HPLC method 1 
(Retention time 3.223 min). 
 
 
 
 
 
(E)-1-(2,4-dihydroxyphenyl)-3-(2-chlorophenyl)-2-propene-1-one. (AH15) 
Recrystalisation from dichloromethane. Dark yellow crystals (%); mp 127-130 oC; TLC: 
Rf  0.34 (hexane/ethyl acetate 7:3); ); IR: (ATR)/cm-1 3234 (OH), 1637 (C=O); 1H 
NMR (δ ppm, DMSO-d6): 6.32 (1H, d, J = 1.2Hz, Ar), 6.45 (1H, dd, J = 8.6, 1.2Hz, 
Ar), 7.44-7.57 (2H, m, Ar), 7.58 (1H, dd, J = 8.6, 1.2Hz, Ar), 8.02 (1H, J = 17.2 Hz, 
C=CH), 8.06 (1H, J = 17.2 Hz, C=CH), 8.23 (2H, m, Ar), 10.85 (1H, s, OH), 13.22 (1H, 
s, OH); 13C NMR (DMSO-d6) 102.6, 108.5, 113.0, 124.2, 127.7, 128.0, 130.0, 132.0, 
132.2, 133.3, 134.4, 138.0, 165.6, 165.8, 190.9; HMRS found [M+1]+ 275.0471, 
C15H12O3Cl [M+1]+ 275.0475; Purity > 98% HPLC method 1 (Retention time 2.960 
min). 
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(E)-1-(2,5-dihydroxyphenyl)-3-(2-ethoxyphenyl)-2-propene-1-one. (AH8) 
Column chromatography. Red/orange powder (60%); mp 89-91oC; TLC: Rf = 0.28 
(hexane/ethyl acetate 7:3); IR: (ATR)/cm-1 3324 (OH), 1639 (C=O); 1H NMR (ppm, 
DMSO-d6): 1.44 (3H, t, J = 4.2Hz, CH3), 4.16 (2H, q,  J =  4.2, 4.2Hz, CH2), 6.85 (1H, 
d, J = 8.3Hz. Ar),  7.04 (2H, dd, J = 8.3, 2.3Hz, Ar), 7.13 (1H, d, J = 8.3Hz, Ar), 7.46 
(2H, ddd, J = 8.3, 1.2Hz, Ar), 7.94 (1H, ddd, J = 8.3, 1.2Hz, Ar), 7.95 (1H, J = 15.5 Hz, 
C=CH), 8.09 (1H, J = 15.5 Hz, C=CH), 9.20 (1H, s, OH), 11.80 (1H, s, OH); 13C NMR 
(DMSO-d6) 14.6, 63.8, 112.7, 114.8, 118.4, 120.7, 121.0, 122.0, 122.8, 124.3, 129.4, 
132.5, 139.3, 149.5, 154.6, 157.8, 159.8, 193.2; HMRS found [M+1]+ 285.1124, 
C17H16O4 [M+1]+ 285.1121; Purity > 98% HPLC method 1 (Retention time 3.744 min). 
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 (E)-1-(2,5-dihydroxyphenyl)-3-(2-methoxyphenyl)-2-propene-1-one. (AH13) 
Column chromatography. Dark red powder (14%); mp 146-149oC; TLC: Rf  0.28 
(hexane/ethyl acetate 7:3) IR: (ATR)/cm-1 3353 (OH), 1638 (C=O); 1H NMR (ppm, 
DMSO-d6): 3.92 (3H, s, OCH3), 6.85 (1H, d, J = 9.5Hz, Ar), 7.00-7.08 (2H, m, Ar), 7.15 
(1H, d, J = 9.5Hz, Ar), 7.44-7.53 (2H, ddd, J = 9.5, 3.2Hz, Ar), 7.89 (1H, J = 16 Hz, 
C=CH), 7.95 (1H, dd, J = 9.5, 3.2Hz, Ar), 8.09 (1H, J = 16 Hz, C=CH), 9.19 (1H, s, OH), 
11.79 (1H, s, OH); 13C NMR (DMSO-d6) 55.8, 111.7, 114.8, 118.3, 120.8, 120.9, 121.9, 
122.7, 124.3, 129.0, 132.6, 139.0, 149.46, 154.6, 158.4, 193.22; HMRS found [M+1]+ 
271.0967, C16H14O4 [M+1]+ 271.0965; Purity > 98% HPLC method 1 (Retention time 
3.083 min). 
 
 
 
 
(E) -1- (2,5-dihydroxyphenyl)-3-(3-chlorophenyl)-2-propene-1-one.  (AH2)   
Column chromatography. Bright red solid (52%); mp 168-170oC; TLC: Rf 0.2 
(hexane/ethyl acetate 7:3); IR: (ATR)/cm-1 3370 (OH), 1644 (C=O); 1H NMR (δ ppm, 
OMe OH
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DMSO-d6): 6.86 (1H, d, J = 8.6Hz, Ar), 7.06 (1H, dd, J = 8.6, 2.9Hz, Ar), 7.45-7.57 (2H, 
m, Ar), 7.57 (1H, d, J = 2.9Hz, Ar), 7.77 (1H, J = 16 Hz, C=CH), 8.01 (1H, J = 16 Hz, 
C=CH), 7.83 (1H, ddd, J = 7.2, 1.4Hz, Ar), 8.08 (1H, s, Ar), 9.20 (1H, s, OH), 11.70, 
(1H, s, OH); 13C NMR (DMSO-d6) 115.3, 118.3, 121.0, 123.9, 124.6, 128.0, 130.3, 130.4, 
130.7, 133.8, 136.8 142.5, 149.5, 154.6, 193.1; HMRS found [M+1]+ 273.0323, 
C15H11O3Cl [M+1]+ 273.0324; Purity > 97% HPLC method 1 (Retention time 3.929 
min).    
 
 
 
 
 
(E) -1- (2,5-dihydroxyphenyl)-3-(4-chlorophenyl)-2-propene-1-one.  (AH3)   
Column chromatography. Bright red powder (22%); mp 187-188oC; TLC: Rf  0.56 
(hexane/ethyl acetate 7:3); IR: (ATR)/cm-1 3383 (OH), 1642 (C=O); 1H NMR (δ ppm, 
DMSO-d6): 6.90 (1H, d, J = 8.8Hz, Ar), 7.10 (1H, dd, J = 8.8, 2.2Hz, Ar), 7.45-7.53 (3H, 
m, Ar), 7.83 (1H, J = 16.0 Hz, C=CH), 7.85-7.95 (2H, m, Ar) 8.02 (1H, J = 16.0 Hz, 
C=CH), 9.20 (1H, s, OH), 11.70, (1H, s, OH); 13C NMR (DMSO-d6) 79.3, 80.2, 83.0, 
88.5, 123.5, 126.3, 128.4, 129.7, 134.3, 136.0, 138.8, 140.6, 154.8, 159.8,  180.6, 190.7; 
HMRS found [M+1]+ 273.0323, C15H11O3Cl [M+1]+ 273.0324; Purity > 97% HPLC 
method 1 (Retention time 2.892 min).    
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(E) -1- (2,5-dihydroxyphenyl)-3-(3-bromophenyl)-2-propene-1-one.  (AH4) 
Column chromatography. Bright red powder (42%); mp 152-154oC; TLC: Rf  0.33 
(hexane/ethyl acetate 7:3); IR: (ATR)/cm-1 3386 (OH), 1635 (C=O); 1H NMR (δ ppm, 
DMSO-d6): 6.82 (1H, d, J = 8.2Hz, Ar), 7.10 (1H, dd, J = 8.2, 2.7Hz, Ar), 7.40 (1H, dd, 
J = 16.4, 8.2 Hz, Ar), 7.55 (1H, d, J = 2.7Hz, Ar), 7.60-7.62 (1H, m, Ar), 7.72 (1H, d, J 
= 16.4 Hz, C=CH), 7.82 (1H, d, J = 8.2Hz, Ar), 8.00 (1H, d, J = 16.4 Hz, C=CH), 8.2 
(1H, s, Ar), 9.20 (1H, s, OH), 11.70, (1H, s, OH); 13C NMR (DMSO-d6); 118.0, 121.0, 
123.6, 125.1, 126.5, 127.3, 131.1, 133.7, 133.7, 135.4, 135.9, 139.7, 145.2, 152.2, 157.4; 
Purity > 96% HPLC method 1 (Retention time 3.786 min).    
  
 
 
 
(E) -1- (2,5-dihydroxyphenyl)-3-(4-bromophenyl)-2-propene-1-one.  (AH5)   
Column chromatography. Bright red powder (17%); mp 188-189oC; TLC: Rf  0.35 
(hexane/ethyl acetate 8:2); IR: (ATR)/cm-1 3390 (OH), 1639 (C=O); 1H NMR (δ ppm, 
DMSO-d6): 6.85 (1H, d, J = 8.5Hz Ar), 7.05 (1H, dd, J = 8.8, 3.4Hz Ar), 7.51 (1H, d, J 
OH
OH
Br
O
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= 3.4Hz Ar), 7.68 (2H, d, J =  6.8Hz Ar), 7.76 (1H, d, J = 13.5Hz, C=CH), 7.86 (2H, d, J 
=  6.8Hz Ar), 7.96 (1H, d, J = 13.5Hz, C=CH), 9.2 (1H, s, OH), 11.7 (1H, s, OH); 13C 
NMR (DMSO-d6) 115.4, 118.3, 121.0, 123.5, 124.5, 130.9, 131.9, 134.1, 142.8, 149.4, 
154.7, 193.0; HMRS found [M+1]+ 316.9817, C15H11O3Br [M+1]+ 316.9819; Purity > 
97% HPLC method 1 (Retention time 2.929 min).    
 
 
 
(E) -1- (2’5’-dihydroxyphenyl)-3-(phenyl)-2-propene-1-one. (AHXRS3) 
Column chromatography. Bright red powder (25%); mp 164-167oC TLC: Rf  0.45 
(hexane/ethyl acetate 7:3); IR: (ATR)/cm-1 3390 (OH), 1639 (C=O); 1H NMR (δ ppm, 
DMSO-d6): 6.86 (1H, d, J = 8.4Hz Ar), 7.04 (1H, dd, J = 8.4, 2.1Hz, Ar), 7.45-7.5 (3H, 
m, Ar), 7.52 (1H, d, J = 2.1Hz Ar), 7.79 (1H, J = 16.8Hz, C=CH), 7.87-7.92 (2H, m, Ar), 
7.93 (1H, d, J = 16.8Hz, C=CH), 9.2 (1H, s, OH), 11.7 (1H, s, OH); 13C NMR (DMSO-
d6) 68.7, 78.7, 87.1, 115.1, 119.0, 121.0, 122.3, 124.8, 126.5, 128.5, 130.8, 134.5, 151.6, 
193.15; HMRS found [M+1]+ 239.0704, C15H12O3 [M+1]+ 239.0703; Purity > 95% 
HPLC method 1 (Retention time 3.044 min).    
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8.2.3.3 Chalcone synthesis method 2 (acid catalysis SOCl2)  modification of (Petrov, 
Ivanova and Gerova, 2008):  
4-hydroxyacetophenone (0.68g 5.55mmol) and 2-chlorbenzaldehyde (0.56mL 
5.55mmol) were dissolved in absolute ethanol (2.5mL). Thionyl chloride (0.25mL mmol) 
was then added dropwise. The reaction mixture was allowed to stir at room temperature 
for 2 hours and then left to stand overnight. The resultant mixture was quenched with 
water (10ml) to induce a precipitate. The resultant precipitate was recrystalised from  
ethanol. 
 
 
 
 
(E)-1-(4’-hydroxyphenyl)-3-(2-chlorophenyl)-2-propene-1-one. (AH16) 
Recrystaliation from ethanol. Purple crystals (33%); mp 167-169oC; TLC: Rf = 0.4 
(hexane/ethyl acetate 7:3); IR: (ATR)/cm-1 3218 (OH), 1649 (C=O) ; 1H NMR (ppm, 
DMSO-d6): 6.91 (2H, dt, J = 9.3, 1.6Hz, Ar), 7.42-7.50 (2H, m, Ar), 7.54-7.59 (1H, m, 
Ar), 7.96 (1H, J = 18.2 Hz, C=CH), 8.01 (1H, J = 18.2 Hz, C=CH), 8.10 (2H, dt, J = 9.3, 
1.6Hz, Ar), 8.18-8.23 (1H, m, Ar), 10.50 (1H, s, OH); 13C NMR (DMSO-d6) 115.4, 124.9, 
127.6, 128.5, 128.8, 130.0, 131.3, 131.7, 132.5, 134.2, 137.3, 162.4, 186.9; HMRS found 
[M+1]+ 259.0523, C15H11O2Cl [M+1]+ 259.0520; Purity > 99% HPLC method 1 
(Retention time 3.110 min).    
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8.2.3.4 Chalcone synthesis method 3 (acid catalysis H2SO4) modification of 
(Konieczny et al., 2007). 
Concentrated sulphuric acid (0.3 mL 5.6 mmol) was added dropwise to a stirred solution 
of the acetophenone (1.64 mmol) and a benzaldehyde (1.81 mmol) in acetic acid (2 mL). 
The reaction mixture was heated for 1hr at 80oC and allowed to cool to room temperature 
and stirred for 24h resulting in the formation of a red precipitate. The reaction was 
quenched with water (30 mL) and extracted with ethyl acetate (2x30 mL). The combined 
organic extracts were washed with water (2x30 mL) and dried over anhydrous magnesium 
sulphate. After the removal of the solvent under vacuum the crude product was 
recrystalised from ethanol.   
 
 
 
 
(E) -1- (2’5’-dihydroxyphenyl)-3-(2-chlorophenyl)-2-propene-1-one.  (AH1) 
Column chromatography. Bright red solid (29%); mp 187-189oC; TLC: Rf 0.55 
(hexane/ethyl acetate 7:3); IR: (ATR)/cm-1 3354 (OH), 1639 (C=O); 1H NMR (δ ppm, 
DMSO-d6): 6.87 (1H, d, J = 8.2Hz, Ar), 7.06 (1H, dd, J = 8.2, 2.7Hz, Ar), 7.49 (3H, m, 
Ar), 7.59 (1H, dd, J = 8.2, 1.4Hz, Ar), 7.96 (1H, J = 16.4 Hz, C=CH), 8.08 (1H, J = 16.4 
Hz, C=CH), 8.18 (1H, dd,  J = 8.2, 1.4Hz,  Ar), 9.20 (1H, s, OH), 11.48, (1H, s, OH); 13C 
NMR (DMSO-d6) 115.1, 118.3, 121.3, 124.5, 125.4, 127.7, 128.7, 130.1, 132.1, 132.1, 
134.4, 138.4, 149.6, 154.3, 192.6; HMRS found [M+1]+ 275.0471, C15H11O3Cl [M+1]+ 
275.0469; Purity > 99% HPLC method 1 (Retention time 3.921 min).    
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(E) -1- (2’5’-dihydroxyphenyl)-3-(2-nitrophenyl)-2-propene-1-one.  (AH12) 
Column chromatography. Bright red solid (27%); mp 190-192oC; TLC: Rf  = 0.20 
(hexane/ethyl acetate 6:4); IR: (ATR)/cm-1 3396 (OH), 1647 (C=O), 1518 (NO2), 1345 
(NO2); 1H NMR (δ ppm, DMSO-d6): 6.88 (1H, d, J = 9.5Hz, Ar), 7.06 (1H, dd, J = 9.5, 
3.2Hz, Ar), 7.45 (1H, d, J = 3.2Hz, Ar), 7.73 (1H, ddd, J = 9.5, 1.2Hz, Ar), 7.84 (1H, d, 
J = 9.5Hz, Ar), 7.88 (1H, J = 15.8 Hz, C=CH), 8.02 (1H, J  = 15.8 Hz, C=CH), 8.14 (2H, 
m, J = 9.5, 1.2Hz, Ar), 9.20 (1H, s, OH), 11.34 (1H, s, OH); 13C NMR (DMSO-d6) 115.1, 
118.4, 121.4, 124.5, 124.7, 127.2, 129.5, 129.6, 131.1, 133.8, 138.1, 148.8, 149.6, 154.1, 
192.3;  HMRS found [M+1]+ 286.0712, C15H11O5N [M+1]+ 286.0710; Purity > 97% 
HPLC method 1 (Retention time 2.573 min).    
 
 
 
 
 (E) – 1 – (3’-hydroxyphenyl)-3-(2-chlorophenyl)-2-propene-1-one. (AH17) 
Column chromatography. Light green solid (20%) mp 112-115 oC TLC: Rf  = 0.35 
(hexane/ethyl acetate 8:2); IR: (ATR)/cm-1 2945 (OH), 1678 (C=O); 1H NMR (δ ppm, 
NO 2 OH
OH
O
OH
Cl O
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DMSO-d6): 7.09 (1H, dd, J = 9.2, 3.1Hz, Ar), 7.40 (1H, dd, J = 15.3, 9.2Hz, Ar),  7.43-
7.52 (3H, m, Ar), 7.59 (1H, dd, J = 9.2, 3.1Hz, Ar), 7.66  (1H, ddd, J = 9.2Hz, Ar), 7.93 
(1H, J  = 15.3 Hz, C=CH), 8.03 (1H, J  = 15.3 Hz, C=CH), 8.23 (1H, dd, J = 9.2, 3.1Hz, 
Ar), 9.90 (1H, s, OH); 13C NMR (DMSO-d6) 117.4, 122.5, 123.3, 127.6, 130.4, 131.3, 
132.6, 132.7, 134.7, 134.9, 137.0, 141.0, 141.3, 160.5, 191.6; HMRS found [M-1] 
257.0377, C15H11O2Cl [M-1] 257.0375 Purity > 95% HPLC method 1 (Retention time 
3.786 min).    
 
 
 
 
(E) -1- (2’-hydroxyphenyl)-3-(2-chlorophenyl)-2-propene-1-one. (AH17a) 
Recrystalisation from ethanol. Light brown crystals (18%) mp 77-81oC TLC: Rf = 0.52 
(hexane/ethyl acetate 9:1); IR: (ATR)/cm-1 2932 (OH), 1639 (C=O); 1H NMR (δ ppm, 
DMSO-d6): 7.02 (1H, m, Ar), 7.44-7.55 (2H, m, Ar), 7.56-7.62 (2H, m, Ar), 8.06 (1H, J 
= 17.8 Hz, C=CH), 8.13 (1H, J = 17.8 Hz, C=CH), 8.22 (2H, dd, 7.4, 1.5Hz, Ar), 12.22 
(1H, s, OH); HMRS found [M+1]+ 259.0523, C15H11O2Cl [M+1]+ 259.0520; Purity > 
97% HPLC method 1 (Retention time 8.386 min).    
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8.2.3.5 Chalcone synthesis method 4 (Detsi et al., 2009) 
The acetophenone (3.23mmol) and benzaldehyde (3.23mmol) were dissolved in absolute 
ethanol (9 mL). Potassium hydroxide (3ml of 20% aqueous solution) was added dropwise. 
The reaction mixture was allowed to stir at room temperature and monitored by TLC. 
After 1 hour the reaction mixture was quenched with cold water (10ml) to induce a 
precipitate. The crude was purified by recrystalisation from ethanol and dried in vacuo. 
 
 
 
 
(E)-1-(2’5’-dimethoxyphenyl)-3-(2-chlorophenyl)-2-propene-1-one. (AH21) 
Recrystalisation from ethanol. Bright yellow crystals (55%); mp 88-92oC TLC: Rf  = 0.63 
(hexane/ethyl acetate 8:2); IR: (ATR)/cm-1  1652 (C=O), 1287 (C-O); 1H NMR (ppm, 
DMSO-d6): 3.74 (3H, s, OCH3), 3.82 (3H, s ,OCH3), 7.07 (1H, dd, J = 1.7Hz, Ar), 7.12-
7.16 (2H, m, Ar), 7.39-7.5 (3H, m, Ar), 7.55 (1H, dd, J = 6.9, 0.1Hz, Ar), 7.8 (1H, J = 
13.8 Hz, C=CH), 7.95 (1H, dd, J = 6.9, 0.1Hz, Ar); 13C NMR (DMSO-d6): 55.6, 56.4, 
113.9, 114.0, 119.1, 127.9, 128.2, 128.8, 129.4, 130.0, 131.8, 132.3, 134.1, 137.3, 152.1, 
153.1, 191.4; HMRS found [M+1]+ 303.0783, C17H15O3Cl [M+1]+ 303.0782; Purity > 
95% HPLC method 2 (Retention time 2.774 min).     
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(E)-1-(2’5’-dimethoxyphenyl)-3-(2-bromophenyl)-2-propene-1-one. (AH21b) 
Recrystalisation from ethanol. Bright yellow crystals (88%); mp 100-102oC TLC: Rf  
0.29 (hexane/ethyl acetate 8:2); IR: (ATR)/cm-1  1665 (C=O), 1015 (C-O); 1H NMR 
(ppm, DMSO-d6): 3.76 (3H, s, OCH3), 3.83 (3H, s ,OCH3), 7.08 (1H, dd, Ar), 7.16 (2H, 
m, Ar), 7.38 (1H, td, Ar), 7.45 (2H, dd, Ar), 7.73 (1H, dd, Ar), 7.79 (1H, d, Ar), 7.94 (1H, 
dd, Ar); 13C NMR (DMSO-d6): 58.3, 59.1, 116.6, 116.6, 121.8, 127.8, 131.1, 131.1, 
131.5, 132.1, 134.8, 136.0, 136.6, 142.7, 154.8, 155.7, 194.2; HMRS found [M+1]+ 
347.0279, C17H15O3Br [M+1]+ 347.0277; Purity > 99% HPLC method 2 (Retention time 
2.945 min).     
 
 
 
(E)-1-(2’6’-dimethoxyphenyl)-3-(2-chlorophenyl)-2-propene-1-one. (AH21a) .  
Recrystalisation from ethanol. Bright yellow crystals (56%); mp 132-139oC TLC: Rf  0.3 
(Hexane/Ethyl Acetate 8:2); IR: (ATR)/cm-1 1652 (C=O), 1251 1102 (C-O); 1H NMR (δ 
ppm, DMSO-d6): 3.72 (6H, s, (OCH3)2), 6.76 (2H, d, J = 8.7Hz Ar) 7.01 (1H, d, J = 
17.4Hz, C=CH), 7.37-7.42 (3H, m, Ar) 7.53 (2H, m, Ar), 7.96 (1H, dd, J = 8.7, 2.2Hz 
Ar); 13C NMR (DMSO-d6): 55.8, 104.4, 117.4, 127.8, 130.0, 130.8, 131.2, 131.8, 132.1, 
OMe
OMeBr O
MeO
OMeCl O
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133.8, 139.4, 156.9, 193.9; HMRS found [M+1]+ 303.0784, C17H15O3Cl [M+1]+ 
303.0782; Purity > 99% HPLC method 2 (Retention time 2.269 min).    
 
 
 
 
(E)-1-(2’6’-dimethoxyphenyl)-3-(2-bromophenyl)-2-propene-1-one. (AH21c) 
Recrystalisation from ethanol. Bright yellow crystals (61%); mp 159-160oC TLC: Rf  0.2 
(hexane/ethyl acetate 8:2); IR: (ATR)/cm-1  1667 (C=O), 1252 (C-O); 1H NMR (ppm, 
DMSO-d6): 3.74 (6H, s, OCH3), 6.78 (2H, d, J = 9.1Hz, Ar), 6.98 (1H, d, J = 15.2Hz, 
C=CH), 7.36 (1H, ddd, J = 12.1, 3.0, 1.5Hz, Ar), 7.43 (2H, m, Ar), 7.51 (1H, d, J = 
15.2Hz, C=CH, Ar), 7.69 (1H, dd, J = 9.1, 1.5Hz, Ar), 7.95 (1H, dd, J = 9.1, 1.5Hz, Ar), 
13C NMR (DMSO-d6): 55.8, 104.4, 117.4, 124.9, 128.4, 128.5, 130.9, 131.2, 132.2, 
133.2, 133.5, 142.3, 156.9, 193.9; HMRS found [M+1]+ 347.0279, C17H15O3Br [M+1]+ 
347.0277; Purity > 99% HPLC method 2 (Retention time 2.483 min).     
 
 
 
 
(E)-1-(2’4’-dimethoxyphenyl)-3-(2-chlorophenyl)-2-propene-1-one. (AH22) 
MeO
OMeBr O
OMe
OMe
Cl O
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Recrystalisation from ethanol. Bright yellow crystals (67%); mp 112-115oC TLC: Rf  
0.23 (Hexane/Ethyl Acetate 8:2); IR: Vmax cm-1 1645 (C=O); 1H NMR (δ ppm, DMSO-
d6): 3.85 (3H, s, OCH3), 3.90 (3H, s, OCH3), 6.67 (2H, m, Ar), 7.43-7.50 (2H, m, Ar), 
7.53-7.66 (3H, m, Ar), 7.83 (1H, d, J = 16.9Hz, C=CH), 7.91-7.96 (1H, m, Ar); 13C NMR 
(DMSO-d6) 55.6, 56.0, 98.6, 106.2, 121.0, 127.8, 128.1, 129.8, 130.0, 131.5, 132.2, 
132.6, 134.0, 135.9, 160.5, 164.3, 189.0; HMRS found [M+1]+ 303.0781, C17H15O3Cl 
[M+1]+ 303.0782; Purity > 95% HPLC method 2 (Retention time 2.578 min).    
 
 
 
 
(E)-1-(2’4’-dimethoxyphenyl)-3-(3-chlorophenyl)-2-propene-1-one. (AH22b)  
Recrystalisation from ethanol. Bright yellow crystals (81%); mp  123-125oC TLC: Rf  0.3 
(Hexane/Ethyl Acetate 7:3); IR: Vmax  cm-1  1648 (C=O); 1H NMR (δ ppm, DMSO-d6): 
3.86 (3H, s, OCH3), 3.90 (3H, s, OCH3), 6.65 (1H, dd, J = 12.4, 2.55Hz, Ar), 6.70 (1H, 
d, J = 2.55Hz, Ar), 7.47 (2H, m, Ar), 7.52 (1H, d, J = 17.1 Hz, C=CH), 7.59 (1H, d, J = 
17.1 Hz, C=CH), 7.63 (1H, d, J = 7.65Hz, Ar), 7.68-7.75 (1H, m, Ar), 7.81 (1H, s, Ar); 
13C NMR (DMSO-d6) 55.6, 56.0, 98.6, 106.0, 121.2, 126.7, 128.0, 128.6, 129.7, 130.7, 
132.1, 133.7, 137.2, 139.4, 160.4, 164.1, 189.2; HMRS found [M+1]+ 303.0780, 
C17H15O3Cl [M+1]+ 303.0782; Purity > 97% HPLC method 2 (Retention time 2.614 
min).    
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(E)-1-(2’4’-dimethoxyphenyl)-3-(2-bromophenyl)-2-propene-1-one. (AH22a) 
Recrystalisation from ethanol. Bright yellow crystals (81%); mp  123-125oC TLC: Rf  0.3 
(Hexane/Ethyl Acetate 7:3); IR: Vmax  cm-1 1648 (C=O); 1H NMR (δ ppm, DMSO-d6): 
3.87 (3H, s, OCH3), 3.92 (3H, s, OCH3), 6.66 (1H, ddd, J = 12.2, 3.05Hz, Ar), 6.71 (1H, 
d, J = 3.05Hz, Ar), 7.36 (1H, ddd, J = 15.3, 6.1, 3.05Hz, Ar), 7.47 (1H, dd, J = 15.3, 
6.1Hz, Ar), 7.56 (1H, d, J = 15.3Hz, C=CH), 7.65 (1H, d, J = 9.2Hz, Ar), 7.73 (1H, dd, 
J = 9.2, 1.5Hz, Ar), 7.81 (1H, d, J = 15.3Hz, C=CH), 7.92 (1H, dd, J = 9.2, 1.5Hz, Ar); 
13C NMR (DMSO-d6) 55.6, 56.0, 98.6, 106.2, 121.0, 124.9, 128.2, 128.4, 129.8, 131.7, 
132.2, 133.3, 134.3, 138.6, 160.4, 164.3, 188.9; HMRS found [M+1]+ 347.0279, 
C17H15O3Br [M+1]+ 347.0277; Purity > 98% HPLC method 2 (Retention time 2.635 
min).    
 
 
 
 
(E)-1-(2’4’-dimethoxyphenyl)-3-(3-bromophenyl)-2-propene-1-one. (AH22s2) 
OMe
OMeBr O
OMe
OMe
Br
O
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Recrystalisation from ethanol. Bright yellow crystals (80%); mp  89-90oC TLC: Rf  0.4 
(Hexane/Ethyl Acetate 7:3); IR: Vmax  cm-1  1648 (C=O); 1H NMR (δ ppm, DMSO-d6): 
3.86 (3H, s, OCH3), 3.90 (3H, s, OCH3) 6.65 (1H, dd, J = 10.0, 2.5Hz, Ar), 6.69 (1H, d, 
J = 1.5Hz, Ar), 7.40 (1H, dd, J = 15, 7.5Hz, Ar), 7.51 (1H, d, J = 15 Hz, C=CH), 7.58 
(1H, d, J = 15 Hz, C=CH), 7.62 (2H, d, J = 7.5Hz, Ar), 7.75 (1H, d, J = 7.5Hz Ar), 7.94 
(1H, s, Ar); 13C NMR, (DMSO-d6) 55.6, 56.0, 98.6, 106.0, 121.2, 122.3, 127.0, 128.6, 
130.9, 131.0, 132.1, 132.6, 137.5, 139.3, 160.4, 154.1, 189.2; HMRS found [M+1]+ 
347.0280, C17H15O3Br [M+1]+ 347.0283; Purity > 98% HPLC method 2 (Retention time 
2.717 min).    
  
 
 
 
(E) -1- (phenyl)-3-(2-chlorophenyl)-2-propene-1-one. (AHXRS1) 
Recrystalisation from ethanol. Bright red crystals (91%) mp 52-54oC TLC: Rf = 0.58 
(hexane/ethyl acetate 8:2); IR: (ATR)/cm-1 1661 (C=O); 1H NMR (δ ppm, DMSO-d6) 
7.48 (2H, m, Ar), 7.60 (3H, m, Ar), 7.70 (1H, tt, Ar), 8.02 (1H, J = 16 Hz, C=CH), 8.07 
(1H, J = 16 Hz, C=CH), 8.18 (2H, dd, Ar), 8.24 (1H, dd, Ar); HMRS found [M+1]+ 
243.0576, C15H11OCl [M+1]+ 243.0577; Purity > 99% HPLC method 2 (Retention time 
2.969 min).    
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8.3. General biology procedures  
8.3.1 Materials 
8.3.1.1 Cell culture 
HUVEC (pooled, P1) Gibco Invitrogen (cat: C-015-10C); EM-200 media Gibco 
Invitrogen (cat: M200500); LSGS Gibco Invitrogen (cat: S-003-10); PBS 7.4 Gibco 
Invitrogen   (cat: 10010023); Trypsin EDTA 10x (cat: T4174); Foetal calf serum (cat: 
C8056); VEGF (recombinant human protein; cat: PHC9394). 
8.3.1.2 MTT assay 
MTT (98%) Sigma-Aldrich (cat: M2128-1G); DMSO (99.6%) (cat: 471267); tissue 
culture plates, 96 well flat bottom with low evaporation lid, Corning Ltd (cat: 353072) 
8.3.2.2 Western blot analysis 
Colour burst ™ electrophoresis protein ladder: 8,000 – 220,000 Da Sigma (cat: C1992) 
Bovine serum albumin (BSA) Sigma (cat: A7906); Sodium orthovanadate (powder) 
Sigma (cat: S6508); DTT Sigma (cat: D0632); Bolt 4-12% Bix-Tris Plus Gels, 10 well, 
gel packs Gibco Invitrogen (cat: NW04120BOX); iBlot™ 2 Transfer Stacks, 
nitrocellulose, regular size  Gibco Invitrogen (cat: IB23001); 20x Bolt MES SDS Running 
Buffer 500ml, Gibco Invitrogen (cat: B0002); TBS: Trizma™ Base, Sigma (cat: T1503); 
NaCl, Sigma (cat: S9888), HCL, Fisher Scientific (cat: 11478333); TBS-Tx100: TBS, 
Triton 100x bio ultra (cat: T9284); Reblot: Re-Blot Plus-Mild (10x), EMD Milipore, (cat: 
2502).  
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Table 21 Buffers and solutions 
 
Table 22 ECL solution 
Solution Volume/concentration Company Cat: 
Solution A (p-coumaric 
acid) 
22 µl of 90 mM Sigma C9008 
Solution B (Luminol) 50 µl of 250 mM Sigma 123072 
Hydrogen peroxide 3 µl of 30% w/w in H2O Sigma 216763 
dH2O 9ml - - 
Tris 1M pH 8.5 1ml - - 
TBST 10x (500ml) 
 Tris (50 mM), NaCl (150 mM), pH adjusted to 7.5 using 
HCl, 0.5% Tween 20. 
TBS Tx-100 (500ml) 450ml dH2O, 50ml TBST 10x, 2.5ml (20%)Triton 100x 
Tris 1M pH 6.8 
Tris base (1 M), 80ml dH20, pH adjusted to 6.8 with 
HCL, made up to 100ml 
Tris 1M pH 8.5 
 Tris base (1 M), 80ml dH20, pH adjusted to 8.5 with 
HCL, made up to 100ml 
Sample buffer (SB) 3x 
3.75ml 1 M Tris pH 6.8, 6.0ml 20% SDS, 6.0ml 100% 
glycerol, 3.0ml 100 mM EDTA pH 6.8, 1.25ml dH2O, 
bromophenol blue 
Laemmli buffer 
600 µl 3x SB, 300 µl dH2O, 0.03g DTT, 80 µl 1 mM 
Sodium orthovandate 
Blocking solution (10ml) 0.5g milk powder, 10ml TBS TX-100 
Stripping buffer (10ml) 1ml, 10x reblot (mild), 9ml dH2O 
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Table 23 Antibodies 
 
All primary antibodies were made up in 5ml of TBSTx-100 with 5% BSA per blot. Secondary 
antibodies were made up in 5ml TBSTx-100 with 5% skimmed milk.  
 
 
 
 
 
 
 
 
 
 
Antibody Dilution Storage Company Cat: 
VEGFR-2 1:1000 -20oC Cell signalling #9698S 
Erk1/2 1:1000 -20oC Cell signalling #9102S 
p-Erk1/2 1:1000 -20oC Cell signalling #4377S 
Β-actin 1:1000 -20oC Cell signalling #8457S 
Anti-rabbit IgG 1:2000 -20oC Cell signalling #7074P2 
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8.3.2 Methods: 
8.3.2.1 General cell culture:  
Primary HUVECs were acquired from Gibco Invitrogen, subcultured and stored in liquid 
nitrogen. Cells were maintained with EM-200 media supplemented with 10% foetal 
bovine serum (FBS) and 50x low serum growth supplement (LSGS).  
8.3.2.2 Preperation of compound solutions  
Compounds were weighed using a Fisherbrand MH-214 series analytical balance scale 
and dissolved with DMSO to make up 100 mM concentration stock solutions. These were 
stored at -20OC. 
8.3.2.3 MTT cell proliferation assay (72 hr)  
The MTT cell proliferation assay was conducted in a 3 stage process.  
Stage 1: Cells were seeded at 3.5 x103 per well in a 96 well plate in a volume of 180 µL 
of 5% serum culture medium. One triplicate per plate was left with no cells as a negative 
control.  Plates were then incubated at 37oC with 5% CO2 overnight. 
Stage 2: Test compound, at 100 mM solution, were diluted down to ranges of 100 µM to 
1µM in fresh 5% serum culture medium, 20 µl of each concentration was added to wells 
in triplicates to form final set of concentrations between 10 µM to 100 nM in media. 
Positive and vehicle controls (H2O2 and DMSO), respectively, at chosen concentrations 
were also made up in 5 % serum culture medium and 20 µl was added to a triplicate of 
wells.  Plates were then allowed to incubate at 37OC with 5% CO2 for 72 hours.  
Stage 3: To each well, 20 µl of 2 mg/ml MTT reagent dissolved in PBS was added and 
then allowed to further incubate for 4 hours at 37OC with 5% CO2. Media was then 
removed and 100 µl of DMSO was added to each well to lyse the cells and solubilise the 
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purple formazan product. The plate was then wrapped in tin foil and then allowed to rock 
for 15 minutes on a Star Lab rocking shaker. Absorbance of each well was 
measured/quantified at 560 nM using a Promega GloMax Disocvery system, data was 
exported to Microsoft Excel and analysed to form % control cell viabilities. Each assay 
was performed 4 times for premlininary screens and 5-6 times for EC/IC50 
determinations.  
8.3.2.4 Cell stimulation and lysate preperation  
HUVECs were grown in 6 well plates until 70-80% confluency. Media was removed and 
washed with PBS and then 1 ml of serum-free media was added. Compounds of known 
concentration with or without VEGF (30 ng/ml – added 15 minutes prior to cell lysate 
collection) were added and incubated for 1 hour. Media was then removed and each well 
washed with cold PBS. 30 µl of laemelli buffer containing sodium orthovandate (protein 
phosphotyrosyl phosphatases (PTP) inhibitor) and dithiothreitol (to break disulphide 
bridges between proteins) was added to each well and placed on ice. Each well was then 
scraped using a Jet Biofil disposable cell scraper and the subsequent cell lysates 
transferred into 0.5 ml eppendorfs. Each cell lysate sample was sonicated using a Qsonica 
sonicator for 20 seconds at 20% pulse amplication. All samples were then heat blocked 
for 5 minutes at 95oC using a Star Lab dry bath system. Then each cell lysates was 
centrifuged for 1 min at room temperature at speed 1,300 rpm using a Heraeus Fresco 21 
centrifuge.  
8.3.2.5 Gel electrophoresis  
Proteins were separated using gel electrophoresis. Pre cast Bolt 4-12% Bix-Tris Plus gel 
packs were used.  Cell lysates prepared as shown in 10.3.2.4 were loaded using Gel Saver 
2 natural pipette tips. In well 2, Colour Burst ™ electrophoresis protein ladder was added 
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to monitor the protein seperation as well as being a standard to compare protein molecular 
weights. Proteins were seperated at 200v using MES running buffer (ingrediance) until 
the loading front reached the bottom of the gel. The gel was then removed from the 
cassette plate.  
8.3.2.6 Transfer of proteins and staining western blotting  
Protein seperated on Bis-Tris Plus Gels were electro-transferred onto nitrocellulose 
membranes using the iBlot™ 2 dry blotting system. Western blot analysis was conducted 
using the Invitrogen mini gel tank and Bolt 4-12% Bix-Tris Plus Gels for gel 
electrophoresis. Gel transfers onto nitrocellulose membranes were carried out using the 
iBlot™ 2 gel transfer device with iBlot™ 2 Transfer Stacks. Selected antibodies were 
used to probe for desired proteins.  
The membranes were briefly washed with TBS-Tx100 and blocked using 5% dried 
skimmed milk in TBS-Tx100 for one hour at room temperature on a gentle rock using 
Star Lab rocking shaker. All antibodies (primary and secondary) were used as shown in 
Table 3. To remove residual primary antibody membranes were washed 3 times with 
TBS-Tx100 for 10 minutes with gentle shaking. HRP-conjugated secondary antibody was 
then added to the membranes for 1 hour followed by 3 TBS-Tx 100 washes for 10 
minutes.  
8.3.2.7 Detection 
All membranes were visualise using the enhanced chemiluminsence (made up in the lab 
see Table 2). Chemiluminsence images were immediately taken using the GeneGnome – 
syngene bio imaging with GeneSys V1.4.1.0 software.  Membrane captures were then 
quantified using densitometry via the Image J software. Levels of proteins were 
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quantified and normalised using β actin as an internal control. Ratio of of phosphorylated 
(activated) protein vs total protein were expressed as means ± SEM.  
8.3.2.8 Scratch assay  
HUVECs were initially cultured in T-75 flasks until 80% confluent before being 
transferred into six well plates (cells of 1 flask split equally into 6 wells).  Six well plates 
were then loaded with 1ml of LSGS media +/- compound at 10 µM, 3 µM and 1 µM 
concentrations. Cells were cultured to 70-80% confluency before being scratched down 
the middle by a p1000 pipette tip.  Images were taken at regular time points (0hr, 4hr and 
8hr) using the EVOS FL Cell Imaging System and the average distance between the 
wound was calculated over the time points as a measure of migration.  Photos were taken 
of 3 randomly selected fields at 100x magnification at 0hr, 4hrs and 8hrs. Three 
independent experiments were carried out. Relevant statistical analyses were performed 
thereafter.  
8.3.2.9 Statistical analysis  
Experiments were conducted in triplicates and repeated at least three times. Ordinary one 
way ANOVA analysis was conducted using Microsoft Excel STAT package. For multiple 
comparative analysis, the Tukey-Kramer multiple comparisons post hoc t-test was used 
via Graphpad Prism 7.0b software.  
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